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ABSTRACT

The immune system is responsible for surveillance against pathogens and malignancies
and adoptive transfer of antigen-specific T is a powerful new cancer treatment option. There is a
clinical need to understand more about the normal regulatory processes that prevent
immunosurveillance and how to manipulate this for clinical benefit. This project aims to
understand T cells from three different angles. First, the biological role of the negative regulator
cereblon (CRBN) was investigated in CD8+ T cells and my studies showed that higher levels of
specific derivatives downstream of the amino acid glutamine may be beneficial to T cells in the
immune microenvironment. Then, the functional role of these specific glutamine metabolites
was studied in antigen-specific CD8+ T cells. Finally, suppressive populations of regulatory T
cells (Treg cells) were measured in patients at risk for skin cancer. Together, these results
expanded our understanding of T cells in various facets of .anti-tumor immunity and immune
surveillance.
Immunomodulatory drugs (IMiDs) potentiate T cell effector functions through cereblon
(CRBN), a substrate receptor of the DDB1-cullin-RING E3 ubiquitin ligase complex. However,
the physiological roles of CRBN in T cells are unclear. Here, we report CRBN expression is
regulated by T cell receptor (TCR) activation and harnesses metabolism of CD8+ T cells. Crbn
deficiency in CD8+ T cells augments cellular metabolism manifest by elevated bioenergetics,
with supraphysiological levels of polyamines secondary to enhanced glucose and amino acid
transport, and increased expression of metabolic enzymes including ornithine decarboxylase.
IMiD treatment similarly augments human CD8+ T cell metabolism. Notably, control of
metabolism by immunomodulatory drugs and Crbn deficiency is linked to increased and
vii

sustained expression of the master metabolic regulator MYC. Finally, while Crbn deficient T
cells exacerbate graft-versus-host disease in vivo, they endow tumor infiltrating lymphocytes
with superior anti-tumor reactivity following adoptive transfer, revealing a new targetable
pathway for adoptive T cell immunotherapy.
Polyamine biosynthesis is a well-conserved metabolic pathway that is increased upon
activation in T cells, though the role that these metabolites serve in activated T cells has not
been fully resolved. Novel implications for the role of polyamines in T cell metabolism and
asymmetric cell division are presented here. First, it was found that antigen-activated CD8+ T
cells prefer glutamine for the carbon source of polyamines over arginine, which can also
produce polyamines as a product of the urea cycle. We also report that glutamine-derived
polyamines are necessary for increased glycolysis observed after T cell receptor activation and
that biosynthetic blockade with pharmacological inhibitors of the rate limiting enzyme ornithine
decarboxylase (OCD) increases the spare respiratory capacity of activated CD8 + T cells.
Further, polyamines act as a critical functional regulator for eukaryotic translation initiation factor
5A (eIF5a) through a process called hypusination. While hypusinated eIF5a is necessary for
normal clonal expansion of antigen-activated CD8+ T cells, it is not involved with the coupled
distribution of CD8 and Myc proteins during asymmetric cell division suggesting that the role of
polyamines in this process is independent of eIF5a. Together, these findings shed light on how
polyamines control normal cellular functions of CD8+ T cells.
Ultraviolet radiation (UVR) causing DNA damage is a well-documented risk factor for
non-melanoma skin cancer (NMSC). Although poorly understood, UVR may also indirectly
contribute to carcinogenesis by promoting immune evasion. We report the first epidemiological
study designed to investigate the association between quantitative measures of UVR, obtained
using a spectrophotometer, and circulating T regulatory (Treg) cells. In addition to total Treg
cells, the proportion of functionally distinct Treg subsets defined by CD45RA and CD27
phenotypic markers, graded expression of FoxP3 and CD25, and those expressing cutaneous
viii

lymphocyte-associated antigen (CLA) and the chemokine receptor CCR4 were enumerated in
350 individuals undergoing routine skin cancer screening exams and determined not to have
prevalent skin cancer. No associations were identified for UVR exposure and the overall
proportion of circulating Tregs. However, Treg subpopulations with an activation-associated
phenotype, CD45RA-/CD27-, and those expressing cutaneous homing receptors were
significantly and positively associated with UVR. These subpopulations of Treg cells also
differed by age, sex, and race. After stratification by natural skin tone, and adjusting for age and
sex, we found that spectrophotometer-based measures of UVR exposure but not self-reported
measures of past sun exposure, were positively correlated with the highest levels of these Treg
subpopulations, particularly among lighter skinned individuals. Findings from this large
epidemiologic study highlight the diversity of human Treg cell subpopulations associated with
UVR, and raise questions about the specific coordinated expression of CD45RA, CD27, CCR4,
and CLA on Treg cells and the possibility that UVR contributes to NMSC carcinogenesis
through Treg-mediated immune evasion.
Here, questions are addressed about fundamental aspects of T cell biology that includes
their role in tumor immune surveillance, translational principles for the design and
implementation

of

novel
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to

human

and

and
mouse

a

comprehensive

experimental

analysis

systems.

of

Through

interdisciplinary approaches, some of the questions about immunobiology and immunotherapy
of cancer have been successfully addressed.
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CHAPTER ONE:
INTRODUCTION
A note to the reader: portions of this chapter have been previously published in a review article
in the journal Medical Sciences, Hesterberg et al. 20181 and in a research article in Journal of
Immunology, Hesterberg et al. 20182.
Introduction to T cell signaling
T cell receptor (TCR) antigen activation is restricted by major histocompatibility cluster
(MHC) and peptide recognition3. T cells lyse their targets (e.g., virally infected or malignant
cells) through interaction of small peptide fragments bound in the groove of an MHC molecule,
which strengthens selectivity for self over non-self and protects against autoimmunity3,4.
Professional antigen-presenting cells (APCs) such as B-cells, macrophages and dendritic cells
(DC) express both MHC class I and MHC class II for activating CD4 + and CD8+ T cells. Through
receptor or phagocytosis-mediated antigen internalization, APCs process antigen into the
correct fragment length for display by the MHC molecule for possible recognition by T cells 5.
The TCR signaling complex engages numerous cascading molecular interactions largely
mediated by phosphorylation, dephosphorylation or ubiquitinylation that result in cellular
activation6 (Figure 1). The TCR complex is composed of several protein that are necessary for
survival and signaling including TCRα and TCRβ chains, the CD3 signaling molecules δ/ε,
CD3γ/ε and CD247 composed on the dimeric ζζ-chains or ζn. The signaling cascade after TCR
recognition of peptides and MHC molecules is complex and leads to effector responses. The
initiating signal is generated by lymphocyte protein tyrosine kinase (Lck) and other Src family
tyrosine kinases, including the zeta-chain associated protein kinase (Zap-70) that is recruited to
the TCR/CD3 complex. Costimulation through leukocyte-associated antigen-1 (LFA1) which is
1

an integrin involved in T cell migration or CD28 interaction with CD80 (B7-1) or CD86 (B7-2)
(see also Figure 1), activates the phosphorylation of the YXXM or YNPP signaling motifs 7 that
regulates glucose metabolism.

CD28 promotes stable recruitment of the adaptor protein

Grb2/GADS along with Itk, Lck, and phosphatidylinositide 3 kinase (PI3K) heterodimer p85/p110
and SLP76.

These interactions promote the activation of VAV-1, RasGRP, and the

Ras/Raf/MEK/Erk pathway downstream of phosphorylated SLP-76 and Zap-70 modulating the
TCR signal strength7. Finally, a complement of transcription factors nuclear factor of activated T
cells (NFAT), cAMP response element-binding protein (CREB), Fox family transcription factor cFos, Jun (when in combination with c-Fos forms the AP-1 early response transcription factor
complex),, an NFκB family member c-Rel, and c-MYC (henceforth referred to as MYC) which
coordinately regulate gene expression. Activation of CD28 leads to the phosphorylation of PI3K,
phosphatidylinositol-3,4 bisphosphate (PIP2) and phosphoinositide-dependent kinase 1
(PDK1)8. These phosphorylation events integrate the TCR and CD28 signaling to induce the
NFκB pathway including protein kinase C-theta (PKC-θ) and inhibit the ubiquitin ligase c-Cbl9.
This ultimately leads to activation of the Bcl10, Malt1, Carma1 (CBM) complex that activates to
IKKαβγ, NFκB, and REL10. In addition to PKC-θ, phosphorylation of AKT is critical for the
regulation of mTORC1 and mTORC2 complexes of mTOR that bind GβL and Raptor or Rictor,
respectively11,12.

This is a critical step in MYC-dependent transcriptional regulation that

stimulates dramatic changes in metabolism including glucose, amino acid, nucleotide and
polyamine biosynthesis 13,14.
Divalent cations such as calcium (Ca2+) are induced downstream of phospholipase Cγ1,
PIP2, and inositol-1,4,5 triphosphate (IP3) which mobilize and release intracellular Ca2+ stores
from the endoplasmic reticulum (Ca2+-ER) a potential metabolic switch that can ultimately
suppress intratumoral T cell functions 15.

Sustained signaling then promotes the influx of

extracellular Ca2+ into the cells through calcium release-activated Ca2+ (CRAC) channels.
Calcium-calmodulin interactions (Ca2+/CaM) then activate the phosphatase calcineurin and
2

calcium/calmodulin-dependent

protein

kinase

type

IV

calmodulin

(CaMKIV),

which

dephosphorylates the cytoplasmic subunits of NFAT. This exposes a nuclear localization signal
that results in nuclear transport and phosphorylation of CREB. This classical TCR signaling
cascade leads to high rates of proliferation, cytotoxic function and cytokine production.
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Figure 1: Proximal T cell signaling cascade. TCR proximal signaling pathways
downstream of the TCR-APC signaling complex are responsible for the cascade of events
leading to reprogramming and differentiation.
T cells express a host of receptors that act as co-stimulatory molecules or as coinhibitors when interacting with various ligands on an antigen presenting cell (Figure 2, Table
1). These molecules promote or repress the functional outcomes of T cells such as cytotoxicityassociated granzyme B expression, cytokine release, and proliferation6,16-27. Co-stimulatory
molecules on T cells were first identified through CD28, which is the founding member of the
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immunoglobulin (Ig) family of costimulatory receptors. Additional receptors include those listed
in Table 1 and Figure 2.
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Figure 2: Stimulatory and inhibitory molecules expressed on T cells.
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Table 1: Coinhibitory and Costimulatory receptors
T Cell
Ligand or protein on
Antigen Presenting Cell
CD28
CD80/CD86
CD40L
CD40
ICOS
ICOSL
CD27

CD70

OX40
LFA1
CD2
HVEM
GITR
TIM1
Galectin 9
4-1BB
CTLA4
PD1
BTLA
CD160
Lag3
Tim3
TIGIT

OC40L
ICAM-1
LFA3
LIGHT, BTLA
GITRL
TIM4
TIM3
4-1BBL
CD80, CD86
PDL1, PDL2
HVEM
HVEM
MHC Class II
Galectin 9
CD155, CD112

Function
costimulatory
costimulatory
Costimulatory, important for
Th2 responses
Costimulatory, memory and
activation
Costimulatory, activation
Costimulatory, T cell migration
Costimulatory, adhesion
Costimulatory
Costimulatory
Costimulatory
Costimulatory
Costimulatory
Coinhibitory
Coinhibitory
Coinhibitory
Coinhibitory
Coinhibitory
Coinhibitory
Coinhibitory

T cell stimulation leads to dynamic changes in metabolic programming that are critical
for the survival and homeostasis of the T cell compartment 28. Similar to tumor cells, T cells must
engage aerobic glycolysis and elevate oxidative phosphorylation (OXPHOS) to promote
antigen-induced growth, proliferation and effector functions 29. Accordingly, impaired metabolism
caused by nutrient-poor environments leads to functional T cell exhaustion in chronic viral
infections and tumors 15,30. Furthermore, signaling invoked by immune checkpoint proteins,
including PD-131, CTLA-432, Tim-333, and lymphocyte-activation gene 3 (Lag3)34, suppress
pathways involved in nutrient utilization, further driving T cell exhaustion. Thus, identifying T cell
metabolic regulators, especially those targetable by small molecule agonists or inhibitors, is
likely to have a dramatic impact on anti-tumor immunity, and on all forms of immunotherapy 35.

5

T cells and cancer
It is essential to maintain a balance between T cell promoting and T cell dampening
signals, such as with the co-receptors. For example, over-activation can lead to autoimmune
diseases driven by T cells and lack of T cell responses can lead to infections, cancer and other
diseases. Cancer, in particular, can create a suite of signals that aid in escaping the immune
system. Normally, cancer cells’ genetic mutations could be recognized as foreign neo-antigens
and over-expressed oncoproteins could increase antigenicity 36. Further, danger-associated
molecular patterns released by unhealthy cells, such as these cancer cells, cause dendritic cells
or other antigen-presenting cells to recruit T cells into the tumor microenvironment for immune
destruction37. This normal mechanism for malignant cells’ destruction is not observed in the
clinic given that cancers grow unfettered despite infiltrating T cells. There are several
mechanisms of evasion from T cells, many of which occur through direc t cell interactions
between the malignant cells and T cells. For instance, cancer cells can down-regulate MHC,
causing a lack of antigen presentation38. Finding mutated antigens can be difficult among all
self-antigens that are not immune stimulatory39. Even if T cells recognize strongly-activating viral
or neo-antigens, cancer cells can over-express ligands that bind to suppressive receptors such
as PD-1 and CTLA4, effectively shutting off TCR signaling40.
There are also several mechanisms of T cell suppression in the tumor microenvironment
that go beyond cell-cell interactions. First, malignant cells can recruit regulatory T cells (Tregs)
that suppress effector T cell responses. These can be recruited by cytokines such as TGF

or

develop from conventional CD4+ T cells by these same cytokines. Further, many of the
repressive signals manifest in conventional CD4+ and CD8+ T cells can activate Treg cells. For
example, PD-L1 causes CD4+ T cells to differentiate into Treg cells and sustains Foxp3
expression, the transcription factor that denotes functional Treg cells 41. Second, another
suppressive cell population that is recruited and thrives in the cancer microenvironment is
comprised of myeloid-derived suppressor cells (MDSCs). These cells can disable the TCR by
6

nitrosylation such that CD8+ T cells can no longer respond to antigens 42. MDSCs can also outcompete T cells for arginine and will release arginase, further depleting this amino acid is
essential for activated T cell survival43,44. Cancer cells also can create a hostile
microenvironment for immune responses occur. Specifically, due to the Warburg effect where
cancer cells have a preference for aerobic glycolysis over other metabolic pathways, there is a
build-up of lactic acid that lowers the pH and inhibits T cell cytokine production 45,46. Cancer cells
can also out-compete T cells for nutrients necessary for activation46. For example, glucose
deprivation caused by the elevated glycolytic rates of cancer cells can significantly impair T cell
function15,47. Given that all these factors can occur at the same time within the tumor
microenvironment, T cells become exhausted and suppressed before proper activation actually
occurs.

The role of CRBN in T cells
Cereblon (CRBN), first discovered through genetic linkage analysis in patients having a
mild autosomal recessive non-syndromic intellectual disability, is the sole documented target of
immunomodulatory drug (IMiD)-induced immune modulation, teratogenicity, and antineoplastic
activity16,48 in multiple myeloma49,50, B-cell malignancies 51-53 and deletion chromosome 5q
myelodysplastic syndrome (del-5q MDS)54,55. From a historical perspective much like the
mammalian target of rapamycin (mTOR), biological functions of CRBN are being revealed due
to its prominent role in IMiD pharmacological responses. CRBN acts as the substrate recruiting
module for the DNA damage-binding protein-1 (DDB1), Cullin 4 (Cul4A or B), and regulator of
Cullins 1 (ROC1) E3 ubiquitin ligase complex56-5 8. Ligation to IMiD compounds modulates the
specificity of the E3-ligase activity and directs the degradation of proteins involved in
hematopoiesis, angiogenesis, and T cell and NK cell regulation52,59-61.
IMiD

compound-induced,

ubiquitin-dependent

degradation

of

the

lymphocyte

transcriptional repressor Ikaros (encoded by IKZF1)62, its paralog Aiolos (encoded by IKZF3)
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63

,

and casein kinase-1α (CK1α), occurs following formation of an interaction interface comprised
of a conserved β-hairpin-loop in these target proteins

59,60,64

. However, pharmacological effects

of IMiD compounds on CRBN functions can also occur via non-proteasome means, where for
example IMiD binding to CRBN displaces it from a complex with CD147 and the lactate
transporter SLC16A1 (MCT1) in multiple myeloma cells, destabilizing this complex and leading
to cancer cell death65. Interestingly, destabilization of the CD147/MCT1 core complex also
occurs after CRBN genetic depletion revealing this as a ubiquitin-independent function.
Human and animal studies imply CRBN regulates two types of ion channel proteins
involved in neuronal excitation, where a nonsense mutation (R419X) within the CRBN Cterminal domain is linked to a nonsyndromic mental retardation syndrome

66

. In other cell types

CRBN appears to control metabolism, by directing degradation of glutamine synthetase (GS)

67

via interactions with acetylated lysines of GS that are triggered by high intracellular glutamine
concentrations, and by suppressing the activity of the α1 subunit of AMP-activated protein
kinase (AMPK α1) 6 8, a regulator of energy homeostasis. Finally, CD4+ T cells from mice lacking
Crbn show increased IL-2 production following T cell receptor (TCR) stimulation, which has
been attributed to the epigenetic regulation of the gene encoding the Kcna3 voltage-activated
potassium ion channel69. This is the basis for research in Chapter Two.

Polyamines in T cell activation
Two of the amino acid precursors for ornithine, glutamine and arginine, are required for
T cell activation7 0-72 and metabolism of these molecules is increased downstream of TCR
signaling events 72, including mTOR, Myc and ERK/MAPK 13,71 that are linked through integrated
signaling (Figure 1). Some studies have suggested that glycolysis is actually less important in
some disease models compared to glutaminolysis 73. Alloreactive TCR stimulation in the context
of graft-versus-host disease (GVHD) was originally considered to be driven largely by
glycolysis 74-76 until it was recently shown, using in vivo tracer studies, that glutamine is the
8

primary fuel source of alloreactive T cells in GVHD 73,75. Furthermore, ODC enzymatic activity is
significantly increased after T cell activation, suggesting that polyamines are produced
downstream of either arginine or glutamine13,77,78.
Mass spectrometry-based global metabolomics and integrated transcriptome analysis
has been used to map the changes in metabolic intermediates after TCR-stimulation44. Notably,
proteins that regulate the arginine and proline pathways are enriched in TCR-stimulated CD4+ T
cells, and metabolic tracing studies have shown that TCR activation triggers flux of Arg into
ornithine, putrescine, and agmatine, and more modest flux into spermidine and proline.
Catabolism of Arg into polyamines in CD4+ T cells is regulated by mitochondrial arginase-2
(ARG2) as arginase-1 is not expressed in these cells. Interestingly, dietary supplementation of
Arg during T cell activation is associated with enhance mitochondrial oxidative phosphorylation
(OXPHOS) and mitochondrial spare respiratory capacity (SRC)28,79,80. Further the morphology
and numbers of mitochondria are critical determinants for SRC and for a functional T cell
memory response following secondary antigenic challenge28,79,80. Notably, in vivo Arg
supplementation of transgenic mice bearing a TCR receptor that specifically recognizes the
hemagglutinin antigen (HA 110–119 peptide) increases intracellular Arg levels and the survival
of memory T cells 44.
Glutamine is also required for long-term T cell responses in vivo and blocking the
metabolism of this amino acid increases short-term effector function while inhibiting long-term
responses 72. Indeed, CD8+ and Th1 CD4+ T cells from mice lacking glutaminase, the enzyme
responsible for the conversion of glutamine to glutamate, have increased expression of the
effector phenotype transcription factor T-bet81,82 and granzyme B. These glutaminase-lacking T
cells fail to exert long-term responses in vivo, suggesting that glutamine is necessary for durable
immunity. A metabolite of glutamine, α-ketoglutarate, is also involved in chromatin accessibility
of various regions of the genome, altering the expression of effector genes 72.
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Although it is evident that arginine and glutamine are involved in memory T cell
development, chromatin accessibility and durable in vivo T cell immunity, a specific role for
polyamines in CD8+ T cell function has not been well-defined. Further, similar to phenotypes
observed in other cell types, polyamines are required for T cell proliferation manifest after TCR
stimulation13,83. Accordingly, although the mechanism(s) is unclear, polyamine depletion during
initial T cell activation in vitro impairs cytotoxic function (CTL) against target cells 84-8 9. This is the
basis of investigation for Chapter Three.

Anti-Tumor Immunity and Polyamines
Polyamines are essential components of T cell activation, where for example they are
necessary for the effector functions and high rates of proliferation

13,84-8 9

. For example, several

older in vitro studies suggest that blocking polyamine production with difluoromethylornithine
(DFMO), an irreversible inhibitor of ODC1, suppresses cytotoxicity of activated CD8+ T cells
against alloantigens or tumor cells 84-89. Surprisingly, several studies have demonstrated that
ODC inhibition90-93 , and/or treatment with polyamine transport inhibitors (PTIs), significantly
reduces rates of tumor growth and that this is due to increase in anti-tumor immunity. Further,
the anti-tumor response is linked to T cell anti-tumor activity, as the beneficial effects observed
following treatment with ODC inhibitors and PTIs are reversed in Rag-/- mice lacking both T and
B cells, and in athymic nude mice that lack only T cells consistent with activation of T cells after
polyamine depletion in tumor models 91,94. Moreover, polyamine inhibition increases CD8+ T cell
infiltration into the tumor bed91,94,95. Though CD8+ T cells isolated from a similar B16F10
melanoma model lack cytotoxic functions in vitro93, it is clear that systemic polyamine inhibition
of tumor-bearing mice can restore T cell anti-tumor immunity.
In the tumor microenvironment, MDSC, Treg and other cell populations suppress the
immune response and contribute to tumor escape from immune surveillance42. These cells also
use polyamines to invoke their suppressive activations and to support their metabolism. MDSCs
10

and other suppressive myeloid cells are evident in many infectious diseases, including
leishmaniasis 96, toxoplasmosis 97, candidiasis

98

, and HIV-infected individuals 99, and are

significantly elevated in tumor-bearing animals 100,101. Comparable suppressive cells have been
identified in both mouse models and human cancers including melanoma, breast cancer,
pancreatic, non-small cell lung and leukemia100.
Suppressive myeloid cells, specifically MDSCs, monocyte-derived M2 macrophages
and some dendritic cells (DCs) are often present in high numbers in the tumor
microenvironment. MDSCs retain the ability to produce NO and high levels of reactive oxygen
species (ROS) leading to nitration of tyrosine residues of the TCR which disrupts its interaction
with the peptide-MHC complex during antigen presentation5 (Figure 2). MDSCs can also inhibit
T

cells

by

high

rates

of

arginase,

depleting

arginine

availability

in

the

tumor

microenvironment102, and DFMO treatment in mice with melanoma results in lower arginase
activity specifically from MDSCs 91 (Figure 3).
Monocyte-derived macrophages can be polarized into M1 or M2 macrophages 95,103,104.
M2 macrophages do not make nitric oxide (NO), a major byproduct of M1 macrophages, and
use arginase to hydrolyze imported arginine into ornithine and urea which depletes arginine in
the tumor microenvironment, compromising intratumoral T cell functions and survival1 00,105,106.
The suppressive functions of M2 macrophages relies on higher basal mitochondrial oxygen
consumption rates driven by fatty acid oxidation (FAO) 107 and, accordingly, the development of
M2 macrophages is blocked by inhibiting mitochondrial OXPHOS and FAO. Further, unlike M1
macrophages, M2 macrophages require glutaminolysis for proliferation and ODC inhibition
through DFMO or polyamine transport inhibitor treatment of tumor-bearing mice significantly
reduces intratumoral suppressive MDSCs 91,94,95 which should improve Arg availability for T cells
that is necessary for their proliferation and persistence44,70,108,109. Polyamine inhibition also
increases TNFα and IL-1 cytokine production by tumor infiltrating macrophages, suggesting
reprogramming of macrophages into the M1 phenotype that augments presentation of tumor11

associated antigens, increases citrulline export and import, and further supports the TCA cycle
via arginine-derived fumarate93,95 (Figure 3). Recently, it has been shown that polyamines
induce IDO1 expression in DCs through Src kinase and that results in a more
immunosuppressive DC phenotype. Inhibition of ODC by DFMO reduces this signaling network
and shifts DCs to a more immune stimulatory phenotype (Figure 3). Thus, it appears that
although polyamines are required for normal CD8+ T cell functions, the net effects of polyamine
depletion on suppressive myeloid cells is to increase anti-tumor CD8+ T cell activity by restoring
a more conducive tumor microenvironment.

Figure 3: Proposed mechanism for DFMO effects on the immune compartment in the
tumor microenvironment.
DFMO treatment inhibits MDSC arginase activity, IDO1 expression on DCs and M2
macrophages. These effects combined decrease MDSC suppressive activity and promote M1
macrophages and immunostimulatory DCs. This allows T cells to import more arginine, an
amino acid transported at a higher rate downstream of the TCR. CD8+ T cells can then produce
more IFNand enhance anti-tumor activity, leading to the apoptosis of malignant cells.
Polyamines in autoimmune disease
Autoimmune diseases are provoked by abnormal, unchecked immune responses
against normal host tissue, and are driven self-reactive TCRs and BCRs in the thymus and
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bone marrow. Further, suppressive immune populations including MDSCs and regulatory T cells
(Tregs), are necessary to establish peripheral tolerance against self-reactive effector T and B
cells that escape negative selection110-1 12. Autoimmunity can arise in almost every peripheral
tissue in the body, for example multiple sclerosis in the brain, thyroiditis and Graves’s disease in
the thyroid, rheumatoid arthritis and ankylosing spondylitis in t he joints, psoriasis, eczema and
scleroderma in the skin, diabetes in the pancreas, and celiac disease, ulcerative colitis, and
Crohn’s Disease that occur in the intestine. Interestingly, circulating polyamine levels are
increased in patients with autoimmune diseases 113,114. Further, polyamines have the ability to
form nuclear aggregates 115- 117 and it has been suggested that nuclear polyamine aggregates
interact with DNA, RNA, or other macro-molecular structures to stabilize autoantigens.
Strikingly, the most common autoimmune B-cell responses are generated to macromolecules
such as double stranded DNA or single stranded DNA118,119. Abnormal polyamine levels have
also been noted in systemic lupus erythematosus (SLE)120, and rheumatoid arthritis 121 that are
characterized by anti-nuclear antibodies consistent with this hypothesis.

Regulatory T cells and UV Radiation
Ultraviolet radiation (UVR) is an environmental factor that contributes to the development
of non-melanoma skin cancer (NMSC), one of the most frequently diagnos ed cancers in the
United States 122,123. The two most common types of NMSC, squamous cell carcinoma (SCC)
and basal cell carcinoma (BCC), occur most often on areas of sun exposed skin
involved in several stages of carcinogenesis

122

123,124

. UVR is

, including induction of DNA damage and

possible immune suppression, enabling malignant cells to grow unchecked. Although the exact
mechanism of the latter is not well understood, immune suppression associated with skin
cancer is marked by both a reduction in conventional T cell functions 125,126 as a consequence of
regulatory T (Treg) cells 127.
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Treg cells, which are characterized by the expression of the transcription factor FoxP3,
CD4 and the IL-2 receptor α chain (CD25), expand systemically and within various tumors
where they uniformly have negative prognostic significance128-130. Differentiation markers on
Tregs have been studied in humans with autoimmune disease, viral infection1 31-134 and cancer,
and include the protein tyrosine phosphatase (encoded by the PTPRC gene) CD45RA, CD62L
(L-selectin) and CD27. While the coordinated differentiation of conventional T cells in humans,
and of Tregs in mice, have been well delineated, the differentiation path for Tregs in humans is
less well defined135. Both CD45RA and CD27, a co-stimulatory molecule involved in activation
and memory development, can functionally distinguish Treg subsets 17,136,137. All of these
markers are expressed on naïve, resting T cells and medullary thymocytes but are
downregulated after T cell receptor activation138 . Patterns of chemokine receptors are also
useful in distinguishing functional Treg populations that exhibit directional localization within
inflammatory environments, including the skin139.
In mice, the frequency of neuropilin-1 +, thymic-derived (i.e., natural) nTregs increased
following exposure to low doses of UVB radiation140 . UVR-induced expansion of Treg cells is
mediated by antigen activation14 1, which, under specified conditions, enables their suppressive
functions and triggers tissue-homing to the skin140,142,143. Antigen activation of Treg cells occurs
through self-antigens and, in some tissues, the microbiome144. The coordination of UVR
exposure and Treg expansion suggests that both may contribute to growth in keratinocyte
carcinogenesis.
Functionally distinct Treg cell subpopulations characterized by specific phenotypic
surface markers have been studied in various disease settings 132,134,145. Thymic-derived Tregs
expressing CD45RA, decline with age in mice146, during chronic viral infections 134, and, following
organ transplantation rejection132. We found previously that CD45RA-/CD27- Treg cells are
expanded prior to disease progression and are specifically associated with poor survival in
myelodysplastic syndrome (MDS)145. Although the CD45RA-/CD27- Treg subset is more
14

suppressive compared to CD45RA-/CD27+ Treg subtypes on an individual cell basis, Treg
population dynamics in the context of UVR, age, sex and race are poorly characterized135,145.
Epidemiological studies have reported associations between prevalence of chronic
autoimmune diseases such as multiple sclerosis, lupus erythematosus, and rheumatoid arthritis,
and distance from the equator, suggesting a role for UVR exposure in immune function147-150.
Other studies using UVR as a treatment for multiple sclerosis and psoriasis have reported
decreased immune function as a result of UVR photochemical therapy, primarily by inducing
Treg cells within the lymph nodes followed by altering their skin migratory behavior

15 1-153

.

Among psoriasis patients, circulating Treg cell populations increase following treatment with
photochemical therapy, suggesting increases in immunosuppressive activity of Treg cells by
UVR154. This is the basis for investigations in Chapter Four.
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CHAPTER TWO:
CEREBLON HARNESSES MYC-DEPENDENT BIOENERGETICS
AND ANTI-TUMOR ACTIVITY OF CD8+ T LYMPHOCYTES

Introduction
Here, using a systems approach to study the physiological roles of Cereblon (CRBN),
we report that CRBN expression is controlled by T cell receptor (TCR) signaling, that CRBN
controls the master T cell metabolic regulator c-Myc (Myc)13, and that deficiency or inhibition of
CRBN invokes a unique T cell metabolic program that overcomes barriers to anti-tumor T cell
immunity, illuminating a new immunotherapeutically tractable pathway that could be exploited in
adoptive T cell therapy.

Results
CRBN is Dispensable for T cell Development but Represses T cell Activation
CRBN expression levels initially decrease following TCR stimulation at both the mRNA
and protein level in mouse (Figure 4A and B) and human CD8+ T cells (Figure 5A), and then
increase to levels higher than those found in unstimulated cells, consistent with a function for
CRBN in harnessing T cell activation. To test this hypothesis, we assessed the roles of CRBN in
controlling T cell functions in Crbn deficient mice

155

, where Crbn deletion was achieved by Cre

recombinase-mediated excision of Crbn exons 3 and 4 after mating with CAG-Cre-expressing
transgenic deletor mice that excised the gene from all tissues (Crbn-/-) (Figure 5B). Consistent
with previous reports of mice with a similar global deletion of Crbn 6 9, normal basal serum levels
of the cytokines IFNγ, IL-2 and TNFα (Figure 5C), as well as CD4+ and CD8+ T cell populations,
16

are equally distributed in Crbn-/- and Crbn+/+ littermates (Figure 5D), which have similar
proportions of CD69+ and CD25+ T cells in the spleen, lymph node, peripheral blood and bone
marrow (Table 2). The distribution of naïve, long-term memory, and effector memory T cells
was also comparable in 3-month old Crbn-/- and Crbn+/+ littermates (Table S1), and the numbers
of thymocytes, and thymic subpopulations, were similar in Crbn-/- and Crbn+/+ mice (Table 2).
Finally, Crbn deficiency had no impact on B cell, NK1.1+ NK cells, or Treg numbers (Table 2).
Homeostatic responses within the T cell compartment were then assessed by evaluating
age-associated T cell phenotypes. Proportions of activated CD44 +CD8+ (Figure 5E) and
CD44+CD4+ T cells (Figure 5F) were similar in Crbn-/- and Crbn+/+ mice with both groups
showing the expected age-dependent increase in CD44 positive cells that are induced through
homeostatic turnover

156,157

. Notably, however, age-associated changes in the memory CD8+ T

cell compartment were significantly different in Crbn-/- mice with the preservation of long-lived
CD44+/CD127+/KLRG1- CD8+ cells (Figure 5G) and corresponding reductions in the
CD44+/CD127-/KLRG1+ (Figure 5H) short-lived memory cells
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suggesting that Crbn

deficiency may regulate CD8+ memory T cell fate.
To assess possible effects of the Crbn deficiency on T cell activation, Crbn-/- and Crbn+/+
T cells were stimulated with anti-CD3ε with or without anti-CD28 costimulation. Notably,
activated Crbn-/- T cells produce significantly increased levels of IL-2 and IFNγ versus Crbn+/+ T
cells even without CD28 costimulation (Figure 4C-D), as well as elevated secreted levels of
TNFα (Figure 4E), IL-17 (Figure 4F) and IL-10 (Figure 5I) and have significantly increased Ifng
mRNA with suboptimal anti-CD3ε (3 µg/mL) (Figure 4G). Finally, there were marked increases
in the number of proliferating CD4+ and CD8+ Crbn-/- T cells, based on the division index (Figure
4H). As a similar proportion of Crbn-/- cells enter cell division as Crbn+/+ cells (i.e., the percent of
T cells that divide, Figure 4H), this suggests Crbn deficiency regulates fitness and/or
persistence of T cells rather than entry into the cell cycle and impacts both cell populations.
Previous analysis of Crbn deficient mice indicated that epigenetic up-regulation of Kcna3 that
17

encodes the voltage-gated potassium channel protein Kv1.3 is mechanistically linked to
hyperactive response in CD4+ T cells

69

, and Kv1.3 is essential for T cell proliferation

159

.

Although activated Crbn-/- CD4+ T cells express higher levels of Kcna3 transcripts 69, we found
no differences in Kcna3 mRNA levels in purified Crbn+/+ versus Crbn-/- CD8+ T cells stimulated
under suboptimal anti-CD3ε conditions, and minimal changes in Kcna3 expression were
observd following anti-CD3ε/anti-CD28-induced activation of either Crbn+/+ or Crbn-/- CD8+ T
cells (Figure 4I, Figure 5J). Thus, other mechanisms likely account for the hyperprolierative
phenotype of Crbn-/- CD8+ T cells.
Given normal serum cytokines and a lack of evidence of spontaneous T cell activation in
Crbn-deficient mice, we reasoned CRBN functions to harness responses provoked by TCR
engagement. To test this notion, TCR signal strength, spontaneous activation, and persistence
was evaluated in antigen-activated Crbn-/- CD8+ T cells, which were generated by crossing Crbn/-

mice to ovalbumin (OVA) peptide TCR-transgenic-(Tg) mice (OT1)

160

. As expected, 96% of

CD8+ splenocytes from Crbn-/-;OT-1 mice displayed TCR reactivity to the H-2Kb OVA tetramer
(Figure 5K). Splenocytes were stimulated with the immunodominant high affinity SIINFEKL
peptide (N4), as well as with a variant OVA peptide with intermediate affinity (SAINFEKL, A2)
that provokes negative selection of immature T cells, or with a very low affinity OVA peptide
(SIIGFEKL, G4) for the OT1 TCR

161

. OT1;Crbn-/- T cells displayed increased proliferation in

response to increasing doses of N4 and A2 peptides compared to wild type OT1 T cells, but did
not respond to the G4 peptide (Figure 4J) or to the OT1-irrelevant melanoma peptide antigen
tyrosinase-related protein 2 (Trp2, SVDFFVWL (Figure 5L). Although OT1 and OT1;Crbn-/- T
cells expressed comparable levels of CD69 in response to the N4 and A2 peptides immediately
after activation, prolonged expression of CD69 (Figure 4K) independent of exogenous IL-2
(Figure 5L) was manifest in OT1;Crbn-/- T cells. Thus, CRBN controls the persistence of
activated T cells after antigen stimulation, but does not lower the threshold of activation or
confer responses to an irrelevant antigen.
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Figure 4: Ablation of Crbn Augments T Cell Activation and Function. CRBN protein (A) and
mRNA (B) expression in 3 µg/mL anti-CD3/anti-CD28 activated mouse CD3+ T cells over time;
densitometry calculations of CRBN normalized to β-actin are displayed below the lanes; (C-F)
Production of IL-2 (C) IFNγ (D) TNFα (E), and IL-17 (F) after 72 hr activation in Crbn +/+ and
Crbn-/- T cells following stimulation with anti-CD3 +/- anti-CD28; (G) Fold change in expression
of Ifng relative to B2M in Crbn+/+ and Crbn-/- T cells following stimulation with anti-CD3 +/- antiCD28 for 12, 24, 48, and 72 hrs; (H) Crbn +/+ and Crbn-/- CD8+ T cell proliferation after 72 hr of
anti-CD3 +/- anti-CD28 stimulation as measured by Cell Trace Violet (CTV) and quantified by
division index (mean number divisions per cell); (I) Kcna3 mRNA levels in purified CD8+ T cells
after activation with anti-CD3+anti-CD28; (J) Total number of OT1 and OT1;Crbn-/- T cells at 72
hr in response to SIINFEKL peptide (N4), SAINFEKL (A2), and SIIGFEKL (G4) as determined
by cell counting with trypan blue dye and flow cytometry for percent viable CD8 + T cells; (K)
CD69 expression in OT1 and OT1;Crbn-/- T cells after 72 hr of culture with 0.1 nM N4 or A2
peptide. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure 5: Deletion of Crbn increases effector function and long-lived memory. (A)
Expression of CRBN protein in human T cells after activation with anti-CD3ε + anti-CD28; (B)
Crbn mRNA levels in the indicated immune tissues or in isolated B cells, T cells, CD4 + T cells,
CD8+ T cells derived from spleen of Crbn+/+ (+), Crbn-/- (-) mice, normalized to Tata binding
protein (Tbp); (C) Levels of IFNγ, IL-2 and TNFα in plasma of Crbn+/+ and Crbn-/- mice; (D)
Percent CD4+ and CD8+ T cells among total CD3+ splenocytes in 3 month old Crbn+/+ and Crbn-/mice; (E-F) CD44 expression on (E) CD8 and (F) CD4 T cells in aging Crbn+/+ and Crbn-/- mice.
(G-H) Percent of cells defined in (E) CD127+KLRG1lo (G) and CD127-KLRG1hi (H) among
CD44+CD8+ T cells; (I) Secretion of IL-10 from plasma defined in Figure 1C-D, F-G; (J) Kcna3
mRNA levels after activation with 3 µg/ml plate-bound anti-CD3+anti-CD28; (K) OVA-reacting
tetramer positive CD8+ splenocytes from OT1 and OT1;Crbn-/- mice; (L) CD69 expression after
72 hr of OT1 and OT1;Crbn-/- splenocytes cultured with 0.1 nM of the indicated peptide with and
without 10 ng/mL IL-2.
20

Table 2: Distribution of Immune Cells in Crbn-/- Mice.

CRBN Controls the Bioenergetics of Activated T cells
To assess if the hyperactivated state of Crbn-/- T cells was associated with changes in
the expression of the IMiD targets Ikaros, CK1α or IRF-4

52,57,64,162

, western blot analyses of

activated Crbn+/+ and Crbn-/- T cells was performed. While IRF-4 was robustly induced following
anti-CD3ε/anti-CD28 stimulation, the expression of Ikaros, CK1α or IRF-4 was not dependent on
Crbn status (Figure 6A). To gain additional insights into the hyperactivated state manifest in
21

-

Crbn-/- T cells, expression profiling of naïve versus anti-CD3ε/anti-CD28-activated Crbn+/+ and

-

Crbn-/- T cells was performed. These analyses revealed activated Crbn-/- T cells expressed 816
unique genes versus activated Crbn+/+ T cells (Figure 6B-D); in contrast, nominal changes in
gene expression were observed in naïve Crbn-/- and Crbn+/+ T cells (Figure 6B). Gene set
enrichment analysis (GSEA) of genes uniquely changed in activated Crbn-/- T cells revealed that
unique transcripts were highly enriched in metabolic and mitochondrial processes (Figure 7A).
In accord with these findings, activated Crbn-/- CD8+ T cells had higher basal rates of glycolysis
and respiration than activated Crbn+/+ CD8+ T cells, based on their extracellular acidification
rates (ECAR) and O 2 consumption rates (OCR) (Figure 7B-C, E-F). Finally, the overall
reduction in OCR observed following oligomycin treatment indicates mitochondrial ATP
production is elevated in Crbn-/- CD8+ T cells in comparison to Crbn+/+ CD8+ T cells (Figure 7E).
Costimulation with CD28 or other costimulatory molecules is normally required to induce
changes in T cell metabolism, and this prevents anergy
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. However, increases in basal ECAR

and OCR were also evident in polyclonal Crbn-/- CD8+ T cells stimulated with anti-CD3ε alone
(Figure 7C, F). Further, increases in bioenergetics were manifest in polyclonal Crbn-/- CD8+ T
cells activated with anti-CD3ε/anti-CD28 (Figure 7C, F) and in OT1;Crbn-/- CD8+ T cells
stimulated with high-affinity peptides versus Crbn+/+ CD8+ T cells (Figure 7D, G). Moreover,
activated CD8+ Crbn-/- T cells display significant increases in glucose uptake (evident by uptake
of the fluorescent glucose analog 2-NBDG, Figure 7H-I), marked increases in hexokinase (HK)
activity (Figure 7J) and a higher NAD+/NADH ratio (Figure 7K), which is consistent with robust
respiration and glycolytic rates
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. Intracellular ATP levels were, however, comparable in Crbn-/-

and Crbn+/+ T cells suggesting that increased generation and utilization of ATP is proportional in
Crbn-/- CD8+ T cells (Figure 7L). Finally, co-treatment with 2-deoxyglucose (2-DG, which blocks
glycolysis) or oligomycin (which suppresses mitochondrial ATPase) abolished or impaired the
proliferative advantage of activated Crbn-/- T cells (Figure 7M-N), respectively. Thus, glycolysis
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is required for the robust metabolic phenotype of Crbn-/- CD8+ T cells and increased OXPHOS
also contributes to their superior proliferative response.
In addition to increases in basal levels of OXPHOS (Figure 7E-G), there was a trend
toward higher spare respiratory capacity (SRC) in anti-CD3ε/anti-CD28 stimulated Crbn-/- T cells
(Figure 7E, 6E). SRC is important for memory T cell (TM) differentiation and mitochondrial
remodeling appears to instruct T cell metabolic programming, where TM manifest fused
mitochondria

28

. Mitochondrial biomass, as assessed by MitoTracker Green staining, was not

significantly increased in activated Crbn-/- CD8+ T cells (Figure 6F). By electron microscopy
some changes in mitochondria were evident in activated Crbn-/- CD8+ T cells, where there were
significant increases in the number of mitochondria (Figure 6G-H) during T cell activation.
However, there were no significant increases in mitochondrial length (Figure 6I), or in total
intracellular or mitochondrial ROS (Figure 6J), which could reflect increases in glutathionine
metabolism manifest in activated Crbn-/- CD8+ T cells (see below, Figure 8B). In contrast, Crbn
deficiency was associated with the expression of classic markers of effector CD8 + T cells (TE),
where there were significant increases in the levels of mRNAs encoding Tbet (T-box 21, Tbx21),
Eomes, granzyme B (Gzmb), and perforin (Prf1) after activation (Figure 7O-R). Thus, Crbn
deficiency promotes differentiation towards a hyperactive effector CD8 + T cell fate following
TCR stimulation.
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Figure 6: Deletion of Cereblon does not significantly alter targets of IMiDs or
mitochondria (A) Immunoblot for proteins that have been described as targets of CRBN in the
context of IMiD compound treatment. Crbn+/+ and Crbn-/- T cells were activated with 5 μg/mL
anti-CD3ε and 1μg/mL anti-CD28 or were left unstimulated; (B) Unsupervised clustering of
transcripts from unactivated (naïve) and 12 hr anti-CD3ε/anti-CD28 activated Crbn+/+ and Crbn-/purified T cells (naïve Crbn+/+, n=3; naïve Crbn-/-, n=2; activated Crbn+/ +, n=3; and activated
Crbn-/-, n=3); (C-D) Volcano plots showing activation-induced mRNA fold change unique to
Crbn+/+ T cells (C) and Crbn-/- T cells (D); (E) Spare respiratory capacity (SRC) of 24 hr activated
Crbn+/+ and Crbn-/- CD8+ T cells, calculated from Figure 6E; (F) Mitotracker Green staining of
naïve and 24- and 72-hr activated Crbn +/+ and Crbn-/- CD8+ T cells; representative of 3
independent experiments; (G-I) Transmission electron microscopy of Crbn+/+ and Crbn-/- CD8+ T
cells 24 hr after activation; (H) Number of mitochondria; (I) average mitochondrial length; (J)
Intracellular ROS and mitochondrial ROS levels in Crbn+/+ and Crbn-/- CD8+ T cells after 24 hr of
activation. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure 7: Cereblon Loss Augments Energetics of Activated T cells. (A) Transcriptional
changes after anti-CD3 and anti-CD28 stimulation of Crbn+/+ T cells, Crbn-/- T cells, or both
(Shared), and analysis of those pathways that only change in Crbn-/- T cells; (B-D) Extracellular
acidification rates of activated Crbn+/+ and Crbn-/- CD8+ T cells (B-C) or N4 peptide-stimulated
OT1 versus OT1;Crbn-/- (D); (E-G) Oxygen consumption rates of activated Crbn+/+ and Crbn-/CD8+ T cells (E-F) or N4 peptide-stimulated OT1 versus OT1;Crbn-/- (G); (H-I) Glucose uptake
of activated Crbn+/+ and Crbn-/- CD8+ T cells with anti-CD3 +/- anti-CD28 as measured by the
fluorescent glucose analog, 2-NBDG mean fluorescent intensity (MFI); (J) Hexokinase activity of
activated Crbn+/+ and Crbn-/- CD8+ T cells; (K) NAD+/NADH ratio of activated Crbn+/+ and Crbn-/CD8+ T cells; (L) ATP production of activated Crbn +/+ and Crbn-/- CD8+ T cells; (M-N) Crbn +/+ and
Crbn-/- CD8+ T cell proliferation after 72 hr of anti-CD3 + anti-CD28 stimulation with 2-DG (K) or
oligomycin (L) treatment; (O-R) Crbn+/+ and Crbn-/- CD8+ T cell qRT-PCR analysis of Tbet
(Tbx21) (O), Eomes (P), Granzyme B (Gzmb)(Q) and Perforin (Prf1) (R) mRNA levels at times
indicated after activation with anti-CD3 and anti-CD28. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001
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Crbn Harnesses Arginine and Glutamine Metabolism and Controls the Expression
of Myc in Activated CD8+ T cells
To assess mechanisms that account for the superior metabolic phenotype of Crbn-/CD8+ T cells, global metabolomic profiling was performed by liquid chromatography-mass
spectrometry in positive and negative ionization modes. MZmine (freeware) was used to identify
and align features, and gap filling was performed to fill in features missed in the first alignment.
Identified features of Crbn+/+ and Crbn-/- CD8+ T cells were then defined by principal component
analysis (PCA) and those with a 2-fold or greater change and p-values ≤ 0.1 were analyzed for
pathway over-representation (Figure 8A-C). Pathway enrichment analysis of differentially
expressed metabolites revealed a highly significant involvement of the “Arginine/Proline”
pathway (Figure 8A-B, FDR 0.006, -log(p) 9.47). A heatmap of these differentially expressed
metabolites revealed anti-CD3ε/anti-CD28 activated Crbn-/- CD8+ T cells have increased
utilization of glutamine, arginine and ornithine and that these cells accumulate high levels of
downstream metabolites, including proline and the polyamines putrescine, spermidine and
spermine (Figure 9A-C).
Both L-arginine (L-Arg) and L-glutamine (L-Gln) can serve as the carbon and nitrogen
units for polyamine biosynthesis

165

. Slc7a1 encoding the L-Arg transporter CAT-1

Slc38a1 (SNAT1) and Slc38a2 (SNAT2) glutamine transporters
glutaminolysis in T cells

167

16 6

, and the

, are required to sustain

13

. Notably, activated Crbn-/- CD8+ T cells express elevated levels of all

three of these transporters (Figure 8D-F, 9B). Moreover, elevated expression of mRNAs
encoding enzymes that catabolize ornithine or direct polyamine biosynthesis, specifically Odc1,
Oat, Srm and Sms, confirmed that this pathway is amplified in activated Crbn-/- versus Crbn+/+
CD8+ T cells (Figure 8G-J, 9B). Further, uptake studies of U-14C-labeled L-Arg and L-Gln
confirmed transport of both amino acids is enhanced in activated Crbn-/- CD8+ T cells (Figure
9D-E) and targeted LC-MS/MS analyses established activated Crbn-/- T cells have supraphysiological intracellular levels of putrescine, spermidine and spermine (Figure 9F-H). Finally,
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the hyper-proliferative state of activated Crbn-/- CD8+ T cells required increases in polyamines,
as this was abolished by treatment with alpha-difluoromethylornithine (DFMO), an irreversible
inhibitor of ODC168 (Figure 9I).
Myc is a master regulator of metabolic transcription programs 169, and in particular
coordinately regulates polyamine metabolism 170 through the transcriptional regulation of Odc1
(Figure 9B). Further, in activated T cells Myc control includes the induction of transporters and
enzymes that direct glutamine catabolism and flux into polyamines 13,165,170. Given the metabolic
phenotypes and augmented glutamine flux into polyamines in activated Crbn-/- CD8+ T cells, we
subjected differentially expressed genes (Figure 7A) to GSEA for transcriptional drivers linked
to differentially-expressed transcripts. These analyses revealed highly significant pathway
enrichment in Myc, Max and Myc/Max-regulated genes (Figure 8K-M), suggesting metabolic
and gene expression changes in activated Crbn-/- T cells are Myc driven. Consistent with this
hypothesis, there were significant increases and sustained levels of MYC protein in CD3 + Crbn-/versus CD3+ Crbn+/+ T cells, and of Myc mRNA in activated Crbn-/- versus Crbn+/+ CD8+ T cells
(Figure 9J and 9K, respectively). Finally, the kinetics of the induction of Myc mRNA following
CD8+ T cell activation paralleled the suppression of Crbn transcripts (Figure 8N), and
supporting the notion that CRBN normally harnesses MYC expression, and MYC-driven
phenotypes, in antigen-activated T cells.
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Figure 8: Activation of Crbn-/- T cells increases Myc-metabolism pathways. (A-C)
Metabolomics analysis of Crbn+/+ and Crbn-/- CD8+ T cells 24 hr after activation; (A-B) Pathway
analysis of metabolite abundance; (C) Principle component analysis of metabolites measured in
positive mode (top) and negative mode (bottom); (D-J) qRT-PCR analysis of the expression of
the indicated amino acid transporters and enzymes relevant to glutamine, arginine and
polyamine metabolism in Crbn+/+ and Crbn-/- T cells without activation or following 24 hr
stimulation with anti-CD3ε and anti-CD28; representative of 2-3 independent experiments; (K-M)
Transcription factor drivers found by GSEA of the changes in activated Crbn-/- T cells shown in
Figure 7A; (N) Myc and Crbn mRNA levels were determined in parallel at the indicated intervals
in wild type CD8+ T cells stimulated with anti-CD3ε and anti-CD28. **p<0.01, **p<0.001,
****p<0.0001
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Figure 9: Crbn Harnesses Arginine and Glutamine Metabolism and Controls the
Expression of Myc in Activated CD8+ T cells. (A-B) Metabolomic analysis of 24hr-activated
Crbn+/+and Crbn-/- CD8+ T cells by LC-MS/MS. (A) Heat map of metabolites that are significantly
different and (B) average fold change in the arginine, glutamine, and proline metabolites; blue
indicates downregulated metabolites in the pathway, pink denotes increased metabolites in the
pathway. mRNA expression for enzymes and transporters for each reaction are shown with fold
change indicated. All enzymes and transporters were upregulated by the fold indicated in Crbn/CD8+ T cells; (C) Structure of the polyamines putrescine, spermidine and spermine; (D-E)
Uptake of L-Arginine and L-Glutamine by Crbn+/+ and Crbn-/- CD8+ T cells after 24 hr of anti-CD3
and anti-CD28 activation; (F-H) Intracellular putrescine, spermidine and spermine levels
measured by LC-MS/MS of activated Crbn+/+and Crbn-/- CD8+ T cells; (I) Crbn+/+ and Crbn-/CD8+ T cell proliferation after 72 hr of anti-CD3 + anti-CD28 stimulation with DFMO treatment;
(J) MYC protein levels in activated Crbn+/+ and Crbn-/- T cells (denoted + and -) were determined
by Western blot analysis at the indicated intervals following stimulation with anti-CD3 + antiCD28; (K) Myc mRNA levels in Crbn+/+and Crbn-/- CD8+ T cells following activation by antiCD3+anti-CD28 for the number of hours indicated. *p<0.05, **p<0.01, ****p<0.0001
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Crbn-Myc Circuit Controls CD8+ T cell Metabolism
Consistent with the findings of increased Myc expression, other Myc -driven responses,
including increases in cell size13,14 and in the expression of the Myc target CD98

171

, were also

manifest in activated Crbn-/- CD8+ T cells (Figure 10A-C). A series of inhibitors have been
identified that block Myc:Max heterodimerization with excellent selectivity and potency (Figure
10D-E).

Co-treatment of activated CD8+ T cells with 10074-G5, an inhibitor of Myc:Max

dimerization172, suppressed the expression of the Myc transcription target Odc1. Additional
Myc:Max dimerization disruptors, MYCMI-11 and MYCMI-617 3, were tested in independent
assays. MYCMI-11 was obtained from the National Institutes of Health, and the synthesis of
MYCMI-6 was derived internally based on previously published structures as detailed in
supplemental methods 173. As expected, disruption of the Myc-Max bHLHZip interaction by these
drugs blocked the expression of Odc1 in Crbn-/- T cells (Figure 10F). Interestingly, the effector
gene signature of Crbn-/- T cells, including Tbx21, EOMES, Gzmb and Ifng, was also decreased
in a dose-dependent manner with co-treatment of 10074-G5 (Figure 10G) or by co-treatment
with MYCMI11 or MYCMI6 (Figure 10H). Thus, the metabolic and TE signature of activated
Crbn-/- CD8+ T cells is Myc dependent.
IMiD-directed proteasomal degradation of Ikaros and Aiolos in multiple myeloma or
lymphoma cells has been linked to subsequent suppression of Myc, and this appears to
contribute to tumor cell death

59,174

. Treatment of human CD8+ T cells with the potent IMiD CC-

122 (avadomide) significantly increased IFNγ secretion especially in cells stimulated with low
levels of anti-CD3ε and anti-CD28 (Figure 11A). To test if a CRBN-MYC circuit was also
manifest in human T cells, activated human CD4+ and CD8+ T cells from healthy donors were
treated with the IMiD compounds lenalidomide, pomalidomide and CC-122. Notably, MYC
protein levels, as measured by mean fluorescence intensity (MFI) (Figure 11B), were increased
by treatment with all three IMiDs, and this effect was more profound in activated CD8+ versus
CD4+ T cells. Further, CD98 expression, uptake of the glucose analog 2-NBDG, OCR, ECAR
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and cell size were also augmented in activated human CD8 + T cells by treatment with IMiDs
(Figure 11C-G, 12A-C, Table 3). Finally, effects of IMiD treatment on 2-NDBG uptake and cell
size were effectively blocked by co-treatment of activated human CD8+ T cells with the Myc/Max
inhibitor 10074-G5 (Figure 11F-5G, Table 3). Thus, IMiD compound modulation of CRBN
function also drives a superior MYC-dependent metabolic circuit in activated human CD8+ T
cells.
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Figure 10: The Phenotypes of Activated Crbn-/- CD8+ T cells Are Myc Dependent. (A) Cell
size (Forward scatter cell-area mean x 1000) of Crbn+/+and Crbn-/- CD8+ T cells after anti-CD3
and anti-CD28 stimulation (72 hr); (B-C) Flow histograms for expression of CD98 in Crbn+/+and
Crbn-/- CD8+ T cells after anti-CD3 and anti-CD28 stimulation for 24 hr; (D) Mechanism of
Myc/Max disruptors; (E) Chemical structures of Myc inhibitors used for analyses; (F-G) mRNA
levels of (F) Odc1 and (G) Tbet (Tbx21), EOMES, Granzyme B (Gzmb), and Ifng in Crbn+/+and
Crbn-/- CD8+ T cells after anti-CD3 + anti-CD28 activation for 24 hr with the indicated doses of
10074-G5; (H) mRNA levels of Tbet (Tbx21), EOMES, Granzyme B (Gzmb), and Ifng in
Crbn+/+and Crbn-/- CD8+ T cells after anti-CD3 + anti-CD28 activation for 24 hr with 30μM
MYCMI-11 or MYCI-6. *p<0.05, **p<0.01, ****p<0.0001

32

Figure 11: Modulation of CRBN by IMiD Compounds Augments Human CD8 + T Cell
Bioenergetics and MYC Expression. (A) Secretion of IFNγ in unstimulated (unstim) and
CC122 treated cells stimulated with increasing doses of anti-CD3 (1,3,and 5) µg/mL plus
constant levels of anti-CD28 for 72 hr; (B) MYC protein levels in unstimulated and anti-CD3 +
anti-CD28 activated human CD8+ T cells treated with IMiD compounds for 5 days as detected
by flow cytometry. IMiDs were tested at 10 µM and include lenalidomide (Len), Pomalidomide
(Pom), avadomide (CC122); (C) CD98 surface expression in activated human CD8 + T cells
treated with IMiD compounds for 5 days; (D-E) O2 consumption rates (OCR) and extracellular
acidification rate (ECAR) after drug treatment; (F-G) Glucose uptake (F) and cell size (G) of
activated (treated with anti-CD3 + anti-CD28) human CD8+ T cells treated with IMiDs +/- the
MYC/MAX dimerization inhibitor 10074-G4, as measured by the fluorescent glucose a nalog 2NBDG (mean fluorescent intensity, MFI) (F) and FSC-A (G). For statistical comparisons see
Table 2. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure 12: Myc, 2-NBDG, CD98 and cell size of IMiD-treated activated human CD8+ T cells.
(A-C) Glucose uptake, represented by 2-NBDG levels (A), CD98 expression (B), and cell size
(C) as measured by forward scatter area (FSC-A), of human CD8+ T cells activated for 5 days
with anti-CD3 and anti-CD28 and treated with the indicated IMiD compounds or the JQ1
inhibitor (as a control, as JQ1 blocks MYC transcription). Data shown are representative of 2-3
healthy donors; numbers indicate MFI of peak shown in histograms.
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Table 3: Statistical comparisons in reference to Figure 11

CRBN Suppresses Extracellular Regulated Kinase (ERK) Signaling to Control MYC
MYC is a potent regulator of cell proliferation and its precise control is critical for
maintaining normal functions and preventing oncogenic transformation. While Crbn-/- T cells
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have increased levels of Myc, restorative processes suppress Myc in the post-activation period.
Myc expression is controlled by several prominent signaling events downstream of TCR
activation and co-activating signals

175

. In T cells, Myc mRNA levels are controlled by the Ca2+-

activated transcription factors Fos/Jun (AP-1)175,176 that are also regulated by ERK1/2 signaling.
Notably suboptimally activated Crbn-/- T cells had significantly higher levels of both total and
phosphorylated ERK1/2 than Crbn +/+ T cells (Figure 13A), suggesting that increased ERK1/2
signaling may be involved in the differential regulation of Myc. Indeed, treatment with the
selective MEK inhibitor PD98059 effectively suppressed levels of total and phospho-ERK1/2 in
activated Crbn-/- T cells and completely suppressed Myc protein levels in these cells (Figure
13A). Strikingly, suppression of ERK1/2 signaling also completely abolished the increases in
Myc mRNA manifest in activated Crbn-/- T cells (Figure 13B). Finally, MEK inhibition also
suppressed the increased expression of the Myc-dependent (see Figure 10G-H) effector genes
Tbx21, Eomes, Gzmb and Ifng in activated Crbn-/- T cells (Figure 13C-F), as well as that of the
Myc target Odc1 (Figure 13G). Collectively, these findings indicate that a Crbn-MEK-ERK1/2
signaling circuit controls the expression of Myc, and Myc-driven phenotypes, in activated T cells.
Following TCR engagement, the activity of several ion channels is induced, including
both K+ and Ca2+ channel proteins, which accumulate at the immunological synapse to generate
intracellular signals

159

. As Ca2+ signaling activates AP-1 (Fos/Jun) complexes, and as Fos/Jun

activity is induced by ERK1/2 signaling, we also assessed effects of the Crbn deficiency on
TCR-mediated Ca2+ flux. Purified CD8+ T cells from Crbn-/- and Crbn+/+ mice were stimulated
with suboptimal levels of anti-CD3ε and anti-CD28 and were treated with thapsigargin (an
irreversible endoplasmic reticulum [ER] Ca2+ adenosine triphosphatase-ATPase inhibitor), which
reduces luminal ER Ca2+ stores and stimulates flux of Ca2+ into the cell via CRAC (Ca2+-release
activating Ca2+) channel activation

177

. Interestingly, thapsigargin-induced Ca2 + influx was

significantly elevated in Crbn-/- versus Crbn+/+ CD8+ T cells (Figure 13H) and in response to
treatment with the Ca2+ ionophore ionomycin (Figure 13I), suggesting a contribution of
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increased intracellular Ca2+ in the enhanced signaling manifest in Crbn-/- CD8+ T cells. Finally,
consistent with increased levels of cytosolic Ca2+, expression of the Ca2+-responsive
Nur77/Nr4a1 orphan steroid receptor,

178

, was significantly elevated in activated Crbn-/- versus

Crbn+/+ CD8+ T cells (Figure 13J).

Figure 13: Myc Expression Elevation in Activated Crbn-/- CD8+ T cells via ERK signaling.
(A) Myc, ERK and pERK protein expression by Western blotting in Crbn +/+ and Crbn-/- CD8+ T
cells with and without 25 μM PD98059 24hr after activation with anti-CD3 and anti-CD28; (B-G)
Crbn+/+ and Crbn-/- CD8+ T cell qRT-PCR analysis of Myc (c-Myc) (C) and Tbet (Tbx21)(D)
Eomes (E), Odc (F), Granzyme B (Gzmb) (G), and Ifng (H) mRNA with 25 μM PD98059 24hr
after activation with anti-CD3 and anti-CD28 in Crbn+/+ and Crbn-/- CD8+ T cells; (H-I) Calcium
flux in Crbn+/+ and Crbn-/- CD8+ T cells that have been after 24 hr of anti-CD3+anti-CD28
stimulation; final concentrations after injections were as follows: 0.5 mM calcium, 10 μM
Thapsigargin (Tg), 1 μg/mL ionomycin (ION); (J) Nr4a1 mRNA levels in Crbn +/+ and Crbn-/CD8+ T cells activated for 24 hr with anti-CD3 + anti-CD28. *p<0.05, **p<0.01, ****p<0.0001
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Crbn Deficiency Augments T Cell Activity in GVHD and Anti-Tumor Immune
Responses, and Myc Expression of CD8+ TIL
To assess the effects of Crbn deficiency on polyclonal T cell activation in vivo to alloantigens, a lethal graft-versus-host disease (GVHD) model was employed, where lethally
irradiated MHC-mismatched Balb/C (H2d) recipients are reconstituted with donor-derived (H2b)
CD3-depleted bone marrow

179

. This is a clinically relevant problem, as toxicity is observed in

multiple myeloma patients receiving IMiDs after allogeneic hematopoietic cell transplantation 180
and AP-1-mediated Myc expression is controls T cell metabolism in patients after stem cell
transplants 181. After randomization, equal numbers of affinity purified H2b C57Bl/6 Crbn+/+ and
Crbn-/- T cells were transferred into lethally irradiated H2d Balb/c mice. Notably, recipients
receiving Crbn-/- T cells displayed a rapid loss in body weight and quickly succumbed to GVHD
(Figure 14A, p=0.017) versus recipients receiving Crbn+/+ T cells. Histopathological analyses of
skin, small intestine and liver (Figure 15A) showed pathology consistent with GVHD

179

. Finally,

there were significantly higher percentages of splenic CD4 + and CD8+ effector T cells
expressing IFNγ in mice receiving Crbn-/- T cells 14-days post-transplant (Figure 14B), yet Crbn/-

and Crbn+/+ donor cells expressed similar levels of the pro-inflammatory cytokines IL-17

(Figure 15B) and IL-5 (Figure 15C), which can provoke tissue toxicity.
The effects of Crbn deficiency on lymphopenia-associated proliferation and memory
conversion through self-antigen engagement were then assessed

156

. T cells from Crbn+/+ and

Crbn-/- littermates were adoptively transferred into sublethally-irradiated syngeneic mice.
Although age-related differences in homeostatic populations were evident in these mice (Figure
5G-H), the division index of both CD4+ and CD8+ T cells, and splenocyte numbers, were equally
distributed among mice receiving Crbn+/+ versus Crbn-/- T cells (Figure 15D-F). Moreover, naïve
T cells that proliferated in response to acute, transient lymphopenia acquired the characteristic
conversion to a memory-like T cell phenotype156 (Figure 15G-H). Thus, Crbn is dispensable for
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T cell development, but regulates the magnitude of the T cell response following TCR
engagement.
Tumoricidal effector functions of tumor infiltrating lymphocytes (TIL) are restricted by low
metabolic resources, including arginine
tumor

183

44

, glutamine

182

and glucose that are utilized by the

, suppressive myeloid populations (MDSCs and suppressive DCs)

prominent expression of inhibitory checkpoint proteins such as PD-1

184,185

, and by the

31

. Given their metabolic

phenotypes and their superior activity in the GVHD model, we hypothesized Crbn-/- T cells might
display superior anti-tumor activity. To test if this was manifest in an adoptive cell therapy (ACT)
scenario, adoptive transfer studies were performed with purified CD8+ T cells from Crbn-/- versus
Crbn+/+ mice in randomized, sublethally irradiated B16 melanoma-bearing mice that were
administered with exogenous IL-2 to support T cell expansion. Importantly, these studies
demonstrated that recipients adoptively transferred with Crbn-/- CD8+ T cells had significant
delays in B16 tumor growth compared to recipients receiving Crbn+/+ CD8+ T cells (Figure 14C).
Thus, Crbn deficient CD8+ T cells have superior anti-tumor activity.
These findings suggested that Crbn-deficient mice should be inherently more resistant to
tumor growth following transplant. To test this, B16 (B16F10) melanoma tumors were injected
subcutaneously into Crbn +/+ and Crbn-/- mice and their tumor growth was monitored. Notably,
tumor progression was significantly suppressed in Crbn-/- recipient mice (Figure 14D-E).
Characterization of immune cells revealed that the percentage of CD45+ hematopoietic cells,
the numbers of CD3+ T cells and Tregs, and the distribution of CD4+ and CD8+ T cells
were similar in the tumors and spleens of both cohorts (Figure 14F, 15I-J). However, activated
populations of CD8+ T cells, including CD44+ and PD-1+ cells, were selectively and significantly
increased (by 2-3 fold) in the TIL from tumors of Crbn-/- versus Crbn+/+ recipient mice (Figure
14G). Interestingly, the T cell exhaustion markers LAG3 and KLRG1 were similar the
intratumoral T cells of the two cohorts (Figure 14G, 15K), suggesting the expanded T cell
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population was activated but avoided the exhausted phenotype characteristic of PD-1expressing TIL

34,186

.

PD-1 receptor engagement normally blocks glucose uptake

31

. Notably, Crbn-/- CD8+ TIL

have a significantly higher representation of PD-1+ 2-NBDGhi cells, indicating these TIL have a
superior metabolic phenotype and are resistant to the effects of PD-1 ligation (Figure 14H). To
determine if TIL manifest in the tumors of Crbn-/- recipient mice are more reactive to tumorassociated peptides, tetrameric proteins were used to detect the melanoma-associated Trp2
antigen expressed in B16 melanoma 187. Within the CD44+ population, Crbn-/- recipient mice had
2-fold more CD44+Trp2+CD8+ TIL than the TIL of Crbn+/+ recipient mice (Figure 14I). Further,
quite strikingly, Myc protein levels were 5-fold higher in Crbn-/- versus Crbn+/+ CD44+Trp2+CD8+
TIL (Figure 14J).
Consistent with the superior anti-tumor reactivity of Crbn-/- TIL, granzyme B levels were
elevated in the CD8+ TIL of Crbn-/- versus Crbn+/+ B16 melanoma-bearing recipient mice (Figure
14K). Finally, OT1;Crbn-/- CD8+ T cells displayed superior cytotoxic activity against OVAexpressing B16 tumor cells versus OT1;Crbn+/+ CD8+ T cells (Figure 15L).
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Figure 14: Crbn-/- T cells Have Superior Anti-Tumor Activity. (A) Effects of graft-versus-hostdisease (GVHD) model of Balb/C mice receiving C57Bl/6 T cell-depleted bone marrow with and
without Crbn+/+ or Crbn-/- T cells (H2b) after lethal body irradiation; percent body weight and
survival of Balb/C H2d recipient mice was monitored at the indicated intervals; (B) Percent IFNγ
producing cells from donor Crbn+/+ or Crbn-/- CD8+ T cells derived from the GVHD model
following re-stimulation with PMA and ionomycin ex vivo on day 14 post-transplant; (C) B16
tumor area in CD45.1+ Crbn+/+ mice randomized to receive Crbn+/+ or Crbn-/- T cells and IL-2
treatment 3 days after tumor inoculation; (D-E) B16 tumor area over time (D) or at day 14 after
tumor inoculation subcutaneously (E) in Crbn+/+ and Crbn-/- recipient mice; (F) CD45+ cell
populations in tumors from the animals noted in (D) and (E); (G) PD-1, Lag3, and CD44 cell
surface expression in CD8+ cell populations in the spleens and tumors from the animals noted in
(D) and (E); (H) PD-1 expression and 2-NBDG uptake in Crbn+/+ and Crbn-/- CD8+ TIL; (I)
Expression of CD44 and reactivity to Trp2 peptide in Crbn +/+ and Crbn-/- CD8+ TIL; (J)
Intracellular Myc expression as measured by flow cytometry in Crbn+/+ and Crbn-/- CD8+ TIL; (K)
Expression of Granzyme B in the indicated TIL. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure 15: Crbn-/- T cells have increased function in vivo. (A-B) in reference to Figure 14AB; (A) H&E of skin, colon and liver from mice in the GVHD model. Arrows indicate immune
infiltrates and areas of pathology; (B-C) Percent IL-17 and IL-5 producing T cells from donor
Crbn+/+ and Crbn-/- following re-stimulation with PMA and ionomycin ex vivo on day 14 posttransplant; (C) Crbn+/+ and Crbn-/- CD45.2+ T cells were adoptively transferred into sublethallyirradiated CD45.1 mice; (D) Schematic of experimental setup; (E) Average number of divisions
of the adoptively transferred CD4+ (left) and CD8+ (right) T cells as determined by CellTrace
Violet dilution; (F) Number of splenocytes after adoptive cell transfer over time; (G) Schematic of
experimental setup; (H) Percent of naïve (CD44NegCD62L+), Effector (CD44+CD62LNeg), and
Central Memory (CM, CD44+CD62L+) of CD4+ T cells and CD8+ T cells from animals noted in
Figure 15D-F; (I-J) CD4+ and CD8+ cell populations and Treg cells (J) in the spleens and tumors
from the animals noted in Figure 14D-E; (K) KLRG1+ cells % of CD8+ TIL from animals noted in
Figure 14D-E; (L) OT1 and OT1;Crbn-/- T cells % cytotoxicity of OVA-expressing B16 cells.
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Discussion
Here we show that targeting CRBN in activated mouse and human CD8 + T cells, either
via genetic means or through small molecule treatment, generates a robust metabolic,
hyperactive CD8+ TE phenotype that has enhanced activity in models of GVHD and anti-tumor
adoptive cell therapy. The latter findings are particularly exciting, as multiple mechanisms
suppress the metabolism of intratumoral T cells 30,44, including nutrient sequestration by
metabolically active tumor cells

4 4,188

, cancer-associated stroma189, MDSCs 5,190, tolerogenic

macrophages and DCs 185,191. Suppressive myeloid cells in particular act as metabolic sinks for
L-Arg and L-tryptophan (L-Trp), which are directly incorporated into proteins, or in the case of LTrp, acts as a substrate for indoleamine 2,3-dioxygenase 1 (IDO1)192,193 that stimulates
CD4+CD25+Foxp3+ Tregs 194. Further, L-Arg depletion triggers downregulation of the TCRζ
chain191, and high levels of nitric oxide generated by MDSCs nitrosylate the TCR-CD8 complex
to induce antigen-specific CD8+ T cell tolerance in tumors 5.
Quite strikingly, CRBN is revealed to harness CD8+ T cell metabolism via control of
MEK/ERK signaling leading to Myc, a master regulator of T cell activation 13 and of asymmetric
division of T cells into effector versus memory cell fates 14. Notably, Green and colleagues have
shown that Myc augments metabolism and enables the proliferation and persistence of CD4 +
and CD8+ T cells via transcriptional reprogramming that includes induction of enzymes directing
glycolysis, glutaminolysis and polyamine biosynthesis

13

. Consistent with high Myc activity,

Crbn-deficient activated mouse CD8+ T cells, and human CD8+ T cells treated with IMiD
compounds, exhibit higher levels of Myc and enhanced nutrient uptake, NAD+/NADH ratios,
glycolytic rates, and basal and reserve capacity for OXPHOS. Further, Myc function is required
to sustain the hypermetabolic phenotype of activated mouse and human CD8+ T cells, as these
are cancelled by treatment with validated inhibitors of Myc:Max function. Thus, a CRBN-MYC
circuit controls the magnitude and persistence of antigen-specific activation of CD8+ T cells, and
drives a hyperactive TE cell fate that has superior anti-tumor activity.
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MYC expression is controlled by several means, including mRNA decay195, ubiquitinmediated protein turnover196, miRNA and lncRNA regulation 197-1 99, transcription200 and
translation201. Thus, the control of Myc mRNA and protein levels in activated T cells, and by
CRBN in this context, is likely complex. Accordingly, it was important to elucidate the
mechanisms that augment Myc expression in Crbn-/- CD8+ T cells. What is known is that there is
both an increase in transcription initiation and repression of a block in transcriptional elongation
associated with Myc mRNA induction17 5. Furthermore, translational regulation of MYC includes
a polyamine-directed pathway202, which we have shown is highly elevated in Crbn-deficient T
cells that rely on polyamine biosynthesis to sustain their hyperactive phenotype. Here we show
that a primary regulator of Myc mRNA and protein expression is MEK/ERK signaling. Precisely
how CRBN harnesses ERK1/2 signaling is not yet clear, though we postulate this may involve
TCR-mediated activation of PLCγ1, that generates diacylglycerol to promotes Ras-ERK
signaling
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, as well as inositol 1,4,5-trisphosphate (IP3) that activates calcium signaling
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which we show is also up-regulated in Crbn-/- CD8+ T cells. Crbn-/- T cells display increased Ca2+
flux after directly triggering CRAC channel activation with thapsigargin treatment and by
ionomycin-mediated activation of IP31 59,204 suggesting CRBN may directly regulate Ca2+ channel
activity to enable sustained Ca2+ influx in these cells. Interestingly, rat CRBN overexpression
suppresses neuron excitation by trapping the BK ca-associated Slo1 protein in the endoplasmic
reticulum (ER) which prevents the maturation and surface assembly of the functional Ca2+
channel205. Alternatively, it is possible that MEK/ERK signaling is somehow linked to CRBNdirected control of the CD147/MCT1 lactate transporter complex that is disrupted by loss of
Crbn or by treatment with IMiDs 65.
Our findings that equal numbers of Tregs and conventional T cells are present in tumorbearing Crbn-/- and Crbn +/+ mice argues for intrinsic roles for CRBN in intratumoral effector T
cells. In addition to nutrient competition, the engagement of multiple checkpoint proteins in TIL
31,32,34,186

blocks uptake and metabolism of glucose and amino acids, by inhibiting PI3K/AKT44

mediated activation of mTOR 33. Therefore, differential early activation signals in Crbn-/- and
Crbn+/+ CD8+ T cells may be critical to fine-tune the distal events that control the duration of the
immune response and metabolic fitness. Checkpoint blockade therapy in particular relies on the
induction of Tbet-associated chromatin remodeling of lineage-selective gene loci to control the
effector phenotype of both CD4+ and CD8+ T cells 81,206,207. Notably, Tbx21 expression is
increased 7-12 fold in activated Crbn-/- CD8+ T cells, consistent with their cytokine production,
gene signature, and metabolic phenotypes. Further, although Tbet is generally associated with
rapid turnover via apoptosis, the balanced expression of Tbet and Eomes as manifest in
activated Crbn-/- CD8+ T cells has been associated with survival and memory formation in the
context of chronic viral infection208.
Other than nutrient supplementation 109, which highly likely also fuels cancer cells and/or
expands immunosuppressive cell populations, there are a no identified targets or strategies that
can selectively enhance the metabolic activity of cytotoxic T cells within the tumor
microenvironment. Thus, our findings that targeting CRBN can augment the activity of T cells in
ACT could have far reaching clinical applications. Furthermore, this work also implicates that
control of effector T cell metabolism may ameliorate GVHD in the clinic. Indeed, Ca2+
mobilization209 and CD98 signaling 171, control by the PD-1/PD-L1 axis 210, and anaplerosis of
alloreactive T cells 73 have all been implicated in GVHD severity, and all three of these
responses appear harnessed by CRBN.
Virtually all anti-cancer therapeutic T cell modalities face the hurdle of inactivation via
exhaustion

29,211

. Our findings of a CRBN-MEK/ERK-MYC circuit (Figure 13) that augments,

sustains and drives an antigen-specific T cell phenotype support the notion that this barrier can
be overcome by pharmacologic or genetic targeting of human CRBN, and that this represents
an attractive accessory to other immune cell therapies, including TIL therapy or chimeric antigen
receptor T cell (CAR-T) therapy. Consistent with this notion, Myc is a Yamanaka stem cell
factor212 and when overexpressed in T cells along with other cooperating stem cell factors, Myc
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can fully revive terminally differentiated CD8+ T cells and maintain antigen specificity213.
Stemness in T cells has been hypothesized to have therapeutic potential for immunotherapy to
preserve the persistence of the cells in vivo214. Notably, the accumulation of long-lived memory
cells in aged Crbn-/- mice also implicates Crbn in the control of memory differentiation.
Consistent with the findings presented herein, we have previously shown that IMiD treatment
reverses tolerance in T cells from MDS patients 215 that display T cell incompetence due to
exhaustion53,21 5-219, which is caused by the accumulation of MDSC 184,220,221, the expansion of
suppressive macrophages and DCs 222, excessive inflammatory cytokine production, the
expansion of Tregs 184, and telomere repair defects 223. The fact that IMiD compounds are
capable of revitalizing T cell responses in MDS suggest that this drug class offers promise as an
adjuvant for immunotherapeutic modalities in many cancer types.

Materials and Methods
Mouse Husbandry
Germline Crbn heterozygous mice (Crbn+/-)155 were obtained from from Dr. Anjali
Rajadhyaksha (Cornell University). Mice were genotyped according to previously established
methods and genotypes were confirmed by genomic PCR and western blots (Figure 3). OT1
transgenic mice160 were bred to Crbn-/- mice for two generations to create OT1;Crbn-/- mice.
C57BL/6 and littermates of Crbn-/- mice were used as Crbn+/+ controls. Mice were genotyped
using methods described by Jackson Lab (https://www.jax.org/jax-mice-and-services) and all
genotyping primers can be found in Table 4. Stocks were maintained and bred at the H. Lee
Moffitt Cancer Center and Research Institute under approved protocols by the Institutional
Animal Care and Use Committee.
Table 4: Cereblon Genotyping Primers
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Mouse Immune Cell Isolation
Spleens were isolated from euthanized Crbn+/+ and Crbn-/- mice and processed into
single cell suspension. Splenocytes were further processed by adding RBC lysis buffer for 1
minute. Pan CD3+ T cells, CD8+ T cells, CD4+ T cells, and B cells were isolated from 6-8 week
Crbn+/+ and Crbn-/- splenocytes by immunomagnetic negative selection.
Mouse Polyclonal CD3+ and CD8+ T cell and Ot-1 CD8+ T cell Activation
For

flow-based assays, RT-PCR, Seahorse analyses, cytokine analysis

and

metabolomics, 96-well round bottom plates were coated with 0.1-10 µg/mL anti-CD3ε in 100 µL
PBS overnight at 4°C or for 90 min at 37°C. Crbn+/+ and Crbn-/- T cells were plated in equal
numbers (2x105 per well) with and without anti-CD28. For cytokine analyses, supernatants were
harvested at 48 hr for IL-2 and IL-17 and at 72 hr for TNFα, IFNγ, IL-10, and IL-4. Cytokines
were quantified from standard curves by enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s protocols. For western blot analysis, 12-well plates were coated
with 5µg/mL anti-CD3ε and 2x106 T cells per well were plated with 1µg/mL anti-CD28. For OT1
and OT1;Crbn-/- activation, whole splenocytes were plated at 106 per well in a 24-well plate and
activated with 0.001-1nM N4, A2, G4, or Trp2 and 10ng/mL IL-2 (unless indicated otherwise).
All T cell experiments were conducted in RPMI supplemented with FBS, Penicillin,
Streptomycin,

Gentamicin,

non-essential

amino

acids,

sodium

pyruvate

and

beta-

mercaptoethanol.
Human T cell Activation
Healthy donor buffy coats were obtained from OneBlood (Tampa, Florida) and were
diluted 1:4 in PBS. T cells were isolated as per manufacturer’s protocol (RosetteSep Human T
cell enrichment Cocktail Kit) and frozen at -80°C in 90% FBS and 10% DMSO before use. 96well round bottom plates were coated with 5µg/mL anti-CD3 in 100µL PBS 90 minutes at 37°C
and placed in 4°C before use. T cells were plated at 2x10 5 per well with 1µg/mL anti-CD28. T
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cells were treated with 10µM lenalidomide, pomalidomide, CC122 or JQ1 for 5 days. All T cells
were analyzed for flow-based assays. For Seahorse assays, CD4+ T cells were removed by
immunomagnetic selection (CD4 microbeads) prior to analysis.
Glucose Uptake and Flow Cytometry Analysis
Antibodies and Trp2 tetramer were added at 0.2 µg per 106 cells in 100-µL volume FACs
buffer (PBS with 2 mM EDTA, 1% FBS and 1% BSA) for 20-30 min at 4ºC. The OVA tetramer
was used for staining of OT1 and OT1;Crbn-/- splenocytes by adding 1.5-µL of the tetramer to
106 cells in 100-µL FACs buffer for 20 min at room temperature prior to antibody
staining. Viability was determined by staining cells with Zombie Near IR dye, Ghost Dye 780 or
Live/Dead Yellow for fixed cells, or with 7AAD and DAPI for fresh isolated cells. Proliferation of
Crbn+/+ and Crbn-/- T cells by dye dilution was determined by staining cells with 5-10 µM
CellTrace Violet for 10 min at 37ºC in PBS prior to activation. Glucose uptake was analyzed by
staining cells with 10 µM 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2NBDG) in PBS for 30-60 minutes at 37ºC degrees. MitoTracker staining was analyzed by
staining cells with 50 nM MitoTracker Green in PBS for 30 min at 37ºC degrees. All data
collection was performed on an LSRII or FACS Canto II (BD Biosciences) and analysis was
performed on Flowjo software.
Experimental Graft-Vs-Host (GVHD) Mouse Model
To induce GVHD, we performed the major histocompatibility complex (MHC)mismatched C57BL/6 to BALB/cJ bone marrow transplant model as described Valenzuela, et al.
179

. Polyclonal Crbn-/- and Crbn+/+ T cells (C57BL/6) were purified to 95% purity using the

negative selection according to manufacturer’s instructions (EasySep Mouse T cell isolation kit).
BALB/c mice were lethally irradiated with 800-900 cGy and injected with 5x106 CD3-depleted
Crbn+/+ bone marrow cells with and without 106 T cells from either Crbn+/+ and Crbn-/- mice via
tail vein 24 hr after irradiation. Weight was measured at the indicated intervals (Figure 14). To
measure function of donor T cells after disease onset, splenocytes were harvested 14 days after
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transplant and re-stimulated with PMA, ionomycin, and 1 µL/mL Brefeldin A. Cells were fixed
and stained for analysis of intracellular IFNγ and IL-17 using protocols and antibodies from BD
Biosciences.
Metabolic Analyses
Seahorse metabolic assays were conducted using activated Crbn+/+ and Crbn-/- CD8+ T
cells or drug-treated human CD8+ T cells were plated in Seahorse base medium supplemented
with 6 mM glucose and 1 mM glutamine at 105 T cells per well in a 96-well Seahorse plate.
Mitochondrial stress tests were used as per manufacturer’s protocol. Extracellular acidification
and oxygen consumption rates were analyzed using Wave Software.
ATP, Hexokinase Enzymatic Assay And NAD/NADH
Crbn+/+ and Crbn-/- CD8+ T cells were activated for 24 hr with anti-CD3ε and anti-CD28
(ATP & NAD/NADH) or 48 hr (HK activity). Analysis was performed as per manufacturer’s
protocol.
Amino Acid Uptake Assays
Arginine and glutamine uptake assays were performed using Crbn+/+ and Crbn-/- CD8+ T
cells that were activated for 24 hr and 3x106 per mouse were suspended in 1x PBS with Ca2+
and Mg2+/0.1% Glucose. 0.2 µCi of the indicated amino acid was added and incubated at room
temperature for 20 min. To stop the reaction, cells were spiked with 1x cold PBS. Cells were
then washed twice with ice cold 1x PBS and subsequently lysed with 0.1% NaOH. The lysate
was mixed with scintillation buffer and counts were determined with a TriCarb 2810 TR liquid
scintillation analyzer (PerkerElmer).
Quantitative PCR Analysis
Cells pellets were kept in Buffer RLT and at -80ºC until RNA isolation. RNA was isolated
as following manufacturer’s protocol (Qiagen) and kept at -20ºC until quantification. RNA was
converted into cDNA as per manufacturer's protocol (Bio-Rad) and 1-2 ng were used to quantify
the expression of the following genes: c-Myc and Crbn by Taqman; Gzmb, Pfr1, Tbx21,
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EOMES, Slc7a1, Slc38a1, Slc1a5, Odc1, Oat, Srm, and Sms by Sybr Green; B2M by Taqman
and Sybr Green. Sybr green probe sequences are listed in Table 5.
Table 5: RT-PCR Primer Sequences

Polyamine Extraction, LC/MS And Quantitation
Extraction. Cell pellets (1 x 106 T cells per replicate, n = 3) were spiked with 5 µL of
internal standard solution containing 1 µg/mL of

13

C4-putrescine, 13C5-ornithine, 1,1,2,2,3,3,4,4-

D8-N-(3-Aminopropyl) Butane-1,4-Diamine:3HCl (D8-spermidine), and 1,1,2,2,3,3,4,4-D8-N,N'Bis(3-Aminopropyl)-1,4-Butanediamine:4HCl (D8-spermine). An aliquot (200-µL) of HPLC grade
methanol heated to 80oC was added to each sample, vortexed and incubated for 5 min at 80oC.
Samples were centrifuged at 16,200 x g for 15 min at 4oC. The extraction process was repeated
using 100-µL of hot methanol at 80oC. The supernatants containing metabolites from both
extractions were pooled and dried in a vacuum centrifuge (Savant SC210A, ThermoFisher
Scientific). Samples were resuspended in 50-µL of HPLC grade water.
Liquid Chromatography-Selected Ion Monitoring. Metabolomics was performed on an
ultra-performance liquid chromatography (UPLC model U3000, Dionex) interfaced with an
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electrospray Q Exactive HF mass spectrometer (ThermoFisher Scientific) using full MS and
selected ion monitoring (LC-SIM) for quantification of each target. The following solvent system
is used: solvent A is 100% HPLC grade water (Burdick & Jackson, Honeywell) containing 0.05%
Heptafluorobutyric acid, and solvent B is aqueous 90% acetonitrile with 0.1% formic acid. For
each sample, a 10-µl aliquot of the metabolite mixture was loaded onto an Accucore reverse
phase C18 column (27826-153030, 2.1 mm x 100 mm, 2.6 µm particle size, ThermoFisher
Scientific). A gradient of 20% B to 80% B was applied over 6 min with a flow rate of 0.350
mL/min followed by re-equilibration over 3 min, for a total of 9 min for the LC experiment. Mass
spectrometry instrument parameters for SIM on the Q Exactive HF included the following:
resolution 70,000; isolation window width 1.0 m/z and isolation offset 0.2 m/z; AGC target 2e5;
maximum IT 100 ms; an inclusion list containing the m/z for each metabolite, its respective
stable isotope standard (SIS) and a scheduled time window for metabolite elution.
Data Analysis for Metabolite Quantification. Xcalibur Quan Browser (version 3.0.63,
ThermoFisher Scientific, San Jose, CA) was used for data analysis. Metabolite amounts (pmol)
were calculated using the peak area ratio of each molecule to its respective.
Gene Set Testing and Pathway Analyses
Unactivated and 12 hr post-activated (5 µg/mL anti-CD3, 1 µg/mL anti-CD28) T cells
from Crbn+/+ and Crbn-/- mice were lysed and total RNA extracted using the iPrep Trizol Plus
RNA kit. One hundred nanograms of total RNA was amplified and labeled with biotin using the
Ambion Message Amp Premier RNA Amplification Kit following the manufacturer’s protocol
initially described by Van Gelder, et al.

224

. Hybridization with the biotin-labeled RNA, staining,

and scanning of the chips on the GeneChip GCS3000 scanner

followed the prescribed

procedure outlined in the Affymetrix technical manual and has been previously described

225

.

The oligonucleotide probe arrays used were the Mouse Genome 430 2.0 Arrays, which contain
over 45,000 probe sets representing over 34,000 transcripts. The array output files were visually
inspected for hybridization artifacts and then analyzed using Affymetrix Expression Console v
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1.4 using the MAS 5.0 algorithm, scaling probe sets to an average intensity of 500. Preprocessing and normalization was then performed using Partek microarray data analysis
software. Raw intensity files were processed using robust multi-array average (RMA). Principle
Component Analysis and unsupervised hierarchical clustering were performed. Statistical
analysis was performed using two-way ANOVA. Gene lists with 2-fold differential expression
and FDR≤0.05 between the unactivated and activated state in Crbn+/+ and Crbn-/- T cells were
compared. Gene Ontology (GO) analysis was performed on genes differentially expressed only
in Crbn-/- T cells following activation using MetaCore by GeneGo. The microarray data have
been deposited to the Gene Expression Omnibus database under accession number
GSE81725.
Transmission Electron Microscopy
Pellets from unstimulated and 24 hr stimulated T cells were fixed immediately in
cacodylate buffer (pH 7.4-7.5) with 2% glutaraldehyde overnight, and resuspended in 1%
osmium tetroxide. Samples were dehydrated step-wise (50%, 70%, 95%, 100%) in increasing
concentrations of alcohol followed by step-wise (2:1, 1:1, 1:2, 0:1 alcohol to resin) infiltration of
resin. Resin blocks were cut on a microtome and images were acquired on a JEOL 1400
transmission electron microscope. Number of mitochondria and average mitochondrial length
was determined by visual inspection using Adobe Photoshop.
Western Blot Analyses
T cells were lysed in RIPA lysis buffer supplemented with protease (Roche
Pharmaceuticals, Pleasanton, CA) and phosphatase (Sigma-Aldrich) inhibitors. 30-40 µg protein
was separated by SDS-PAGE on 4-12% gradient Bis-Tris gels using Novex Protein Separation
System (Thermo Fisher Scientific). Antibodies used are indicated in the Key Resources Table.
Densitometry was performed on 600 dpi greyscale images using ImageJ software
(http://imagej.nih.gov/ij/) and values were normalized to β-Actin.
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Experimental Melanoma Mouse Model and Act
Mice were injected with 1x105 B16 melanoma cells subcutaneously on the left flank.
Tumors were measured every 2-3 days by taking two perpendicular measurements and volume
was calculated by the equation “a x b 2 x 0.52” where a is the longest measurement and b is the
perpendicular measurement. Mice were euthanized when tumors ulcerated or the longest side
exceeded 20 mm. Some cohorts of mice were euthanized early (day 10-14) for TIL analysis by
flow cytometry. Tumors for this analysis were processed into single cell suspension and agitated
for 30 min in complete RPMI (noted above) supplemented with Collagenase I, Collagenase IV,
Hyaluronidase, and DNAse I. Populations of T cells from spleens and tumors were stained as
described and immediately analyzed. For adoptive cell transfer, CD45.1 mice were sublethally
irradiated 3 days after initial tumor inoculation at 600rad and 2x10 6 T cells were injected via tail
vein. Mice were then treated with 250,000 I.U. IL-2 (R&D Systems) via intraperitoneal injections
twice daily for 3 days (6 total doses).
Homeostatic Proliferation
CD45.1 mice were sublethally irradiated at 600rad and 2x105 CellTrace Violet-labeled
Crbn+/+ and Crbn-/- T cells were injected via tail vein. Average number of divisions (division
index) and memory populations were analyzed among spleen populations on day 7 after
adoptive cell transfer.
Metabolomics Analysis
Sample preparation. Samples were thawed on ice then centrifuged at 20,000 x g for 5
minutes at 4 oC to pellet the cells. Supernatants were discarded and the pellets were washed
with 1 mL of 40 mM ammonium formate. The samples were mixed on a vortex and then
centrifuged at 20,000 x g for 5 minutes at 4 °C and supernatants were discarded. The wash
step was performed 2 more times. To each sample, 50 µL of 5 mM ammonium acetate and 1020 pieces of 0.7 mm zirconia beads were added. Homogenization was done on a Bead Beater
(BioSpec, Bartlesville, OK) at 1800 rpm for 30 seconds. Samples were incubated at 4°C for 30
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min. Protein concentrations were determined using Qubit Protein Assay kit. Prior to extraction,
samples were normalized to 300 µg/mL or to the lowest protein concentration by diluting to 50
µL with 5 mM ammonium acetate. Each sample received 10 µL of internal standards solution,
containing creatine-D3 H2O, L-Leucine-D10, L-tryptophan-2,3,3-D3, Citric acid 13C6, L-tyrosine
Ring 13C6, L-tryptophan 13C11, L-leucine 13C6, L-phenylalanine Ring-13C6, N-BOC-L-tertleucine, and N-BOC-L-aspartic acid. Samples were extracted by protein precipitation using 1
mL ice-cold 80% methanol/20% water and mixed on the Bead Beater (BioSpec Products) at
1,800 rpm for 30 seconds. Further protein precipitation was allowed by incubating the samples
at 4 oC for 30 minutes. Samples were centrifuged at 20,000 x g for 5 minutes at 4 oC to pellet
the protein. An aliquot of the supernatant (1 mL) was transferred from each sample into clean
tube and dried under a gentle stream of nitrogen at 30°C. Dried extracts were re-suspended
with 30 µL reconstitution solution consisting of injection standards in 0.1% formic acid in water
containing 6 µg/mL of Boc-L-tyrosine, Boc-L-tryptophan, and Boc-D-phenylalanine.
Resuspension was allowed at 4°C for 10 -15 minutes; then, samples were centrifuged at 20,000
x g for 5 minutes at 4°C. Supernatants were collected into clean LC-vials for LC-MS
metabolomics analysis.
LC-MS. Global metabolomics profiling was performed on a Thermo Q-Exactive Orbitrap
mass spectrometer with Dionex UHPLC and autosampler. All samples were analyzed with
positive and negative heated electrospray ionization with a mass resolution of 35,000 at m/z 200
as separate injections. Sheath gas and auxiliary gas flow rates were set at 50 and 10,
respectively, with auxiliary gas temperature of 350°C. Spray voltage was set to 3.0 kV and
capillary temperature to 325°C. Mass range was from m/z 70 to 1000 with MS acquisition for
17.5 minutes. Separation was achieved on an ACE 18-PFP 100 x 2.1 mm, 2 µm column (MACMOD Analytical, Chadds Ford, PA) with mobile phase A as 0.1% formic acid in water and
mobile phase B as acetonitrile. The flow rate was 350 µL/min with a column temperature of
25°C. Total LC run time was 20.5 minutes. The initial condition of 100% A at 0.35 mL/min was
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held for 3 minutes then a linear gradient from 0-80% B for 10 min. To wash the column, 80% B
was held for 3 min before going back to 0% B. For each sample, 4 µL was injected for negative
ion analysis and 2 µL for positive ions.
Data processing. Data from positive and negative ion modes were processed separately.
LC-MS files were first converted to open-format files (i.e. MzXML) using MSConvert
(Proteowizard 3.0.10095). MZmine 2.23 was used to identify features, deisotope peaks, align
features and perform gap filling to fill in any features that may have been missed in the first
alignment algorithm 226. All adducts and complexes were identified and removed from the data
set prior to statistical analysis.
Statistical analyses were performed separately on the positive and negative ion data
including both previously identified and unknown metabolites. Metaboanalyst 3.0227 was used
for statistical analysis using unpaired peak intensity tables in column format exported from
MZmine. Data integrity, missing data estimation, and data filtering were first performed on the
data set. Normalization of the samples to allow adjustment of differences among the samples
was performed using normalization by sum (i.e. total ion signal). Log transformation and
autoscaling were selected.

Univariate analysis by ANOVA was performed. Chemometric

analysis including Principal Component Analysis (PCA) and Partial Least Squares -Discriminant
Analysis (PLS-DA) were conducted. Unsupervised clustering with visualization in a heat map
was also done on the data set.
Compound Synthesis & Verification
CC-122 and MYCMI-6 compounds were synthesized in collaboration with the Moffitt
Chemical Biology Core. Steps for synthesis of these two drugs are displayed in Figure 16. Both
compounds’ purities were checked by NMR and HPLC.

55

Figure 16: Synthesis of compounds CC-122 & MYCMI-6
(A) Synthesis of CC-122; Reagents and conditions. (a) 200 °C, 30 min, 85%; (b) Pyridine, 140
°C, 18 h, 23%; (c) Pd(OH)2, H2 (balloon), DMF, rt, 12 h, 51%; B: Synthesis of MYCMI-6;
Reagents and conditions. (d) NaNO2, HCl, 0 °C; 2. HBF4; (e) 1. 2N HCl; 2. NaOAc.
Cytotoxicity Assays
B16-OVA target cells (gift from Dr. S Pilon-Thomas) were treated with 10ng/mL of IFNγ
for 2 hours at 37oC and re-plated in a flat-bottom 96-well plate. Activated OT1 and OT1;Crbn-/were then added at a 5:1 T cell to target ratio for 6 hours. LDH release in the media as per
manufacturer’s protocol and percent of target cells lysed was determined by the following
equation:
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝐿𝐷𝐻 − 𝑇 𝑐𝑒𝑙𝑙 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻 − 𝐵16𝑂𝑉𝐴 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻
𝑥100
𝐵16𝑂𝑉𝐴 𝑡𝑜𝑡𝑎𝑙 𝐿𝐷𝐻 − 𝐵16𝑂𝑉𝐴 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻

Statistical Analysis
P values were determined using GraphPad Prism Software (GraphPad Software, Inc, La
Jolla, CA) by Student’s t test, Mantel-Cox Log-rank test, or two-way ANOVA as listed in figure
legend. Equal variance is assumed between groups. All data represented as mean with error
bars representing ± standard error. Number of animals in each group is listed in figure legends
for experiments entailing biological replicates. Technical replicate experiments are
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representative of 2-3 independent experiments and contain 3-6 replicates. Group sizes were
based on prior experience with similar studies.
Critical Resources and Reagents
Critical assays, reagents, and mice purchased from commercial sources or received
from academic sources are listed in Table 6.
Table 6: Critical Reagents and Resources For Chapter Two
REAGENT or RESOURCE
Antibodies
CRBN
c-Myc
IKZF1
CK1α
IRF4
Monoclonal Anti-Actin antibody produced in mouse
CD3e Monoclonal Antibody (145-2C11), Functional
Grade
CD28 Monoclonal Antibody (37.51), Functional Grade
CD3 Monoclonal Antibody (HIT3a), Functional Grade
CD28 Monoclonal Antibody (CD28.2), Functional Grade
CD69-PE-CF594
CD3, mouse, multiple fluorochromes used
CD3-APC, human
B220, mouse, multiple fluorochromes used
CD19,mouse, multiple fluorochromes used
NK1.1, mouse
CD8α, mouse, multiple fluorochromes used
CD4, mouse, multiple fluorochromes used
CD25-APC, mouse
Vα2-PE, mouse
Vβ5-FITC, mouse
CD98-PE, mouse
CD98-PE, human
CD44-BV510
CD127-PE-Cy7, mouse
KLRG1-BV421, mouse
IFNγ
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SOURCE

IDENTIFIER

Abcam
Cell Signaling
Technology
Cell Signaling
Technology
Cell Signaling
Technology
Cell Signaling
Technology
Sigma
ThermoFisher

#ab139408
#5605

ThermoFisher
ThermoFisher
ThermoFisher
BD Biosciences
Biolegend, BD
Biosciences or Tonbo
Tonbo
BD Biosciences or
Biolegend
Biolegend or
Invitrogen
BD Biosciences
Biolegend, Tonbo or
BD
Biolegend, BD
Biosciences or Tonbo
Tonbo
eBioscience
eBioscience
Biolegend
BD Biosciences
Biolegend
Biolegend
Biolegend
BD Biosciences

#16-0281-81
#16-0039-81
#16-0289-85
Clone: H1.2F3
Clone: 17A2

#5443
#2655
#4948
#A4700
#16-0031-81

Clone: UCHT1
Clone: RA3-6B2
Clone: 6D5
Clone: PK136
Clone:53-6.7 or 2.43
Clone: GK1.4 or
RM4-5
Clone: PC61.5
Clone: B20.1
Clone: MR9-4
Clone: RL388
Clone: UM7F8
Clone: IM7
Clone: A7R34
Clone: 2F1/KLRG1
Clone: XMG1.2

Table 6 (Continued)
IL-17A

BD Biosciences

IL-5
c-Myc, human/mouse, multiple colors used

BD Biosciences
Cell Signaling
Technology
eBioscience
Tonbo
Sigma

Foxp3, multiple fluorochromes used
PD1-PE
B-actin
Biological Samples
Human PBMCs
Chemicals, Peptides, and Recombinant Proteins
OVA (257-264)
OVA-A2 Peptide, SAINFEKL, OVA (257-264) Variant
OVA-G4 Peptide, SIIGFEKL, OVA (257-264) Variant
TRP - 2 (180 - 188)
Recombinant Murine IL-2
Recombinant Murine IFNγ
2-Deoxy-D-glucose
Oligomycin A
13
C4-putrescine
13

C -ornithine
5

1,1,2,2,3,3,4,4-D -N-(3-Aminopropyl) Butane-1,4Diamine:3HCL
1,1,2,2,3,3,4,4-D8-N,N'-Bis(3-Aminopropyl)-1, 4Butanediamine:4HCL
HPLC Grade Water
HPLC Grade Methanol
HPLC Grade Acetonitrile
Formic Acid
Accucore C18 Column 150 x 3.0 mm, 2.6 µm
Ionomycin
Fluo4AM
Heptafluorobutyric acid
Hyaluronidase V
Collagenase type I
Collagenase type IV
DNAse I
JQ-1
10074-G5
RIPA buffer
Recombinant Mouse IL-2 Protein
13
L-TYROSINE (RING- C6, 99%)
8

13

L-TRYPTOPHAN ( C11, 99%)
13

L-LEUCINE ( C6, 99%)
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Clone: TC1118H10.1
Clone: TRFK5
Clone:D84C12
Clone: FJK-16s
Clone: J43.1
#A3854-200

One Blood, St
Petersburg, FL

N/A

Anaspec
Anaspec
Anaspec
Anaspec
Peprotech
Peprotech
Sigma
Sigma
Cambridge Isotope
Labs
Cambridge Isotope
Labs
Cambridge Isotope
Labs
Cambridge Isotope
Labs
Honeywell Chemicals
Honeywell Chemicals
Honeywell Chemicals
Thermo Fisher
Thermo Fisher
Thermo Fisher
Thermo Fisher
ProteoChem
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
R&D Systems
Cambridge Isotope
Labs
Cambridge Isotope
Labs
Cambridge Isotope
Labs

#AS-60193-1
#AS-64383
#AS-64384
#AS-61058
#212-12
#315-05
#D8375
#75351
# CLM-6574
#CLM-4724
#DLM-9262
#DLM-9262
#AH3654
#AH2304
#AH0154
#PI28905
#27826-153030
#I24222
#F14217
#LC6206
#H6254
#SCR103
#C5138
#DN25
#SML0974
#G3798
#R0278
#402
#CLM-1542
#CLM-4290-H-PK
#CLM-2262-H-PK

Table 6 (Continued)
13

L-PHENYLALANINE (RING- C6, 99%)
N-BOC-L-tert-Leucine, 98%
N-BOC-L-Aspartic acid, 99%
BOC-L-Tyrosine, 99+%
Nalpha-BOC-L-Tryptophane, 97%
BOC-D-Phenylalanine, 99+%
Calcium Chloride
Creatine-d3 H2O (methyl-d3)
D-Leucine-d10
L-Tryptophan-2,3,3-d3
Water with 0.1% Formic Acid (v/v), Optima™ LC/MS
Grade
13
Citric acid ( C6, 99%)
GLUTAMINE, L-[14C(U)]

Arginine L-[14C(U)]
Critical Commercial Assays
IFN gamma Mouse ELISA Kit
Seahorse XF Cell Mito Stress Test Kit
Mouse IL-2 Recombinant Protein, eBioscience
Mouse IL-17 Quantikine ELISA Kit
Mouse IL-10 Quantikine ELISA Kit
Mouse TNF-alpha Quantikine ELISA Kit
Mouse IFN-gamma Quantikine ELISA Kit
Mouse IL-4 Quantikine ELISA Kit
Pierce™ LDH Cytotoxicity Assay Kit
Hexokinase Activity Assay Kit (Colorimetric)
NAD/NADH-Glo™ Assay
GeneChip™ Mouse Genome 430 2.0 Array
Qubit Protein Assay Kit
MessageAmp™ Premier RNA Amplification Kit
ATPlite Luminescence Assay System, 300 Assay Kit
Deposited Data
Microarray data
Experimental Models: Cell Lines
B16-F10
B16-OVA
Experimental Models: Organisms/Strains
C57Bl6
CD45.1
OT1
BALB/cJ
-/Crbn
Oligonucleotides
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Cambridge Isotope
Labs
Acros Organics
Acros Organics
Acros Organics
Acros Organics
Acros Organics
Sigma
CDN isotopes
CDN isotopes
CDN isotopes
Fisher Scientific

#CLM-1055-0

Cambridge Isotope
Labs
American
Radiolabeled
Chemicals
Perkin Elmer

#CLM-9021

ThermoFisher
Agilent
Invitrogen
R&D systems
R&D systems
R&D systems
R&D systems
R&D systems
Thermo Fisher
Abcam
Promega
Thermo Fisher
Thermo Fisher
Thermo Fisher
Perkin Elmer

#KMC4022
#103015-100
#14-8021-64
#M1700
#M1000B
#MTA00B
#MIF00
#M4000B
#88953
#ab136957
#G9071
#900495
#Q33211
#AM1792
#6016943

Gene Expression
Omnibus

GSE81725

ATCC
N/A

#CRL-6475

Jackson
Jackson
Jackson
Jackson

#000664
#002014
#003831
#000651
N/A

#368010010
#303210010
#275700050
#275690050
#275740050
#C4901
#D-1972
#D-5607
#D-7419
#LS1184

#ARC0196-50

#NEC267E050UC

Table 6 (Continued)
Mm00487804_m1 Myc
Mm01182414_m1 Crbn
Mm00437762_m1 B2m
Mm00446971_m1 Tbp
RT-PCR Primers (Supplemental Table)
Genotyping primers (Supplemental Table)
Software and Algorithms
Graphpad V7
Flowjo V10
Metaboanalyst 4.0

ThermoFisher
ThermoFisher
ThermoFisher
ThermoFisher
IDT
IDT

#4331182
#4351372
#4331182
#4331182
N/A
N/A

GraphPad Software
BD
http://www.metaboana
lyst.ca/
Thermo Fisher
Partek, Inc.
Thomson Reuters
http://imagej.nih.gov/ij/
http://mzmine.github.io
/
http://proteowizard.sou
rceforge.net/
Agilent Technologies

Xcalibur Quan Browser
Partek
Gene Go
ImageJ
MZmine
MSConvert
Wave version 2.6
Other
Pan T cell Isolation Kit II, mouse
CD8a+ T cell Isolation Kit, mouse
CD4+ T cell Isolation Kit, mouse
B cell Isolation Kit, mouse
CD3e Microbead Kit, mouse
EasySep™ Mouse T Cell Isolation Kit
RosetteSep Human T cell Enrichment Cocktail
CD4 Microbeads, human
Leukocyte Activation Cocktail, with BD GolgiPlug™
CellTrace Violet
iTAgiTAg Tetramer/PE – H-2 Kb OVA (SIINFEKL)
2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4yl)Amino)-2-Deoxyglucose)
Zombie NIR
Ghost Dye Red 780
MitoTracker Green
7-AAD
DAPI (4',6-Diamidino-2-P henylindole, Dihydrochloride)
Live/Dead Yellow
CD3 Microbead Kit
Power SYBR™ Green PCR Master Mix
Taqman Universal PCR Master Mix
iPrep™ Trizol™ Plus RNA Kit
eBioscience™ Foxp3 / Transcription Factor Staining
Buffer Set
TM
iScript Reverse Transcription Supermix for RT-qPCR
RNeasy Plus Mini Kit
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Miltenyi
Miltenyi
Miltenyi
Miltenyi
Miltenyi
Stemcell
Stemcell
Miltenyi
BD Biosciences
Molecular Probes
MBL
Molecular Probes

#130-095-130
#130-104-075
#130-104-454
#130-090-862
#130-094-973
#19851
#15061
#130-045-101
#550583
#C34557
#T0300
#N13195

Biolegend
Tonbo
Thermo Fisher
BD Biosciences
Thermo Fisher
Molecular Probes
Miltenyi
Thermo Fisher
Thermo Fisher
Thermo Fisher
Thermo Fisher

# 423105
#13-0865-T500
# M7514
#559925
#D1306

Bio-Rad
Qiagen

#1708841
#74134

#130-094-973
#4367659
#4304437
#IS10007
#00-5523-00

Table 6 (Continued)
RPMI Media
Zirconia Beads
iTAg Tetramer/APC - H-2 Kb TRP2 (SVYDFFVWL)

Thermo Fisher
Biospec Products
MBL
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#11875
#11079107zx
#T03015

CHAPTER THREE:
THE ROLE OF POLYAMINES IN ACTIVATED CD8+ T CELLS

Introduction
It remains to be determined what role polyamines serve in CD8+ T cells aside from a
well-defined role in proliferation13. Here, we report how polyamines are generated in activated
CD8+ T cells, and using DFMO to block polyamine production, we demonstrate that this
pathway controls glycolysis, IFNγ production, and is necessary for asymmetric division.

Results
Glutamine is carbon source of polyamine biosynthesis in antigen-activated CD8+
T cells
The OT-1 mouse model with defined specificity for the OVA-derived peptide, SIINFEKL
(N4), is a useful model to investigate pathways involved in the antigen activation of CD8 + T cell.
SIINFEKL peptide treatment for 24 hours activates oxygen consumption and extracellular
acidification of OT-1 CD8+ T cells relative to treatment with the tyrosinase-related protein 2
(Trp2) used as a non-activating peptide control (Figure 17A-B). Broad expression of amino acid
transporters is evident within 24 hours in activated versus non-activated OT-1 cells (Figure
17C). These transporters include the general glutamine transporter, SLC1A5, the arginine
cation transporter, SLC7A1, other cationic family members, the large subunit of the neutral
amino acid transporter CD98, SLC3A2, and two glutamine transporters relevant to T cell
biology, SLC38A1 and SLC38A2, suggesting that these cells can actively transport many amino
acids including glutamine and arginine. Both arginine and glutamine can serve as carbon
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sources in the biosynthesis of polyamines, and the influx of both

14

C-L-Arg and

14

C-L-Gln is

specifically induced after stimulation with the N4 versus Trp2 peptide (Figure 17D).

To

determine if polyamine levels and the polyamine biosynthetic pathway is relevant after antigen
activation, we studied the expression of Odc mRNA and enzyme function, Oat, Aldh18a1, Srm,
and Sms enzymes in OT-1 cells receiving N4 and Trp2 treatment (as shown in Figure 17E-G)
and indicated schematically in Figure 17F Notably, all of these enzymes were increased in
activated OT-1 CD8+ T cells.
Given that both arginine and glutamine uptake is significantly increased with TCR
stimulation, activated CD8+ T cells were labeled with

13

C-arginine or

13

C-glutamine to fully label

the intracellular arginine and glutamine pools (Figure 18A-C). Activated CD8+ T cells labeled
with

13

C-glutamine had significantly higher incorporation of carbons into ornithine, putrescine,

spermidine, and spermine compared to pools labeled from

13

C-arginine (Figure 18D) despite

the higher levels of arginine uptake (Figure 18D) in activated T cells. This suggests that
polyamine pools may be primarily derived from the precursor glutamine. Indeed, overall
intracellular levels of

13

C-glutamine were significantly decreased compared to

13

C-arginine,

suggesting that glutamine may be more actively metabolized following activation (Figure 18E).
To confirm that polyamines are derived from glutamine, activated CD8+ T cells were cultured
with the glutamine antagonist, 6-Diaza-5-oxo-L-norleucine (DON) to block glutaminase activity.
Intracellular ornithine and polyamines were decreased by treatment with DON (Figure 18F),
confirming that glutamine contributes to polyamine biosynthesis in antigen-activated CD8+ T
cells.
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Figure 17: Antigen activation of CD8+ T cells increases glutamine and arginine
metabolism. (A-B) Oxygen consumption (OCR) and extracellular acidification (ECAR) rates of
OT-1 CD8+ T cells activated with N4 or Trp2 peptides for 24 hours; (C) RT-PCR for amino acid
transporters; (D) Uptake of 14C-Arginine and 14C-Glutamine; (E) Relative ornithine
decarboxylase; (F) RT-PCR for enzymes in the ODC & polyamine pathway
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Figure 18: Polyamines are primarily derived from glutamine. (A) Isotope labeling strategy
for fully-labeled arginine (orange) and glutamine (blue). Colored dots represent 13C molecules
measured against fully black molecules to calculate apparent fractional labeling (AFL); (B-C)
Percent of 13C-Arginine and 13C-Glutamine among total arginine and glutamine; (D) Percent 13COrnithine, 13C-Putrescine, 13C-Spermidine and 13C-Spermine among total of these molecules;
(E) Total intracellular glutamine and arginine levels; (F) Total intracellular ornithine and
polyamine levels with and without DON treatment during activation.
Polyamine production is necessary for expression of T-box transcription factors
involved in the CD8+ effector phenotype and for viability
Given the significant increase in polyamine production after TCR activation, the role of
polyamines in the phenotype of activated CD8+ T cells was next assessed with the ODC
inhibitor, difluoromethylornithine (DFMO) (Figure 19A) that blocks the rate-limiting step of
polyamine biosynthesis 168. Expression of early activation markers, CD69 and CD25, were not
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altered by DFMO treatment (Figure 19B), demonstrating that ODC blockade does not impact
the TCR activation signaling cascade that leads to the expression of early activation antigens
(as detailed in the Introduction). The Tbx21 gene, encoding the transcription factor T-bet, and
the gene eomesodermin (Eomes) are critical regulators of CD8+ T cell function and
differentiation81,82,22 8 and differentially regulate short-and long-lived memory precursor
populations 229,230. Titrating down T-bet expression, especially relative to Eomes, has been
associated with shorter-lived cells because Eomes can induce CD122 (IL-2Rβ chain) that is
responsible for IL-15 signaling, a cytokine that drives CD8+ T cell memory231. In addition to
effector and memory differentiation, T-bet and EOMES are differentially associated with T cell
exhaustion during viral infection and during cancer immunotherapy. A T-betdim Eomes hi
expression profile has been linked to better long-term viral control during chronic human
immunodeficiency virus infection232 but higher T-bet-expressing CD8+ T cells is associated with
effector functions of tumor infiltrating cells 233. Treatment with DFMO decreases the proportion of
T-bet expressing CD8+ T cells post-activation but does not change the expression of Eomes
(Figure 19C-D), suggesting that polyamine blockade could increase long-term T-betdim Eomes hi
memory populations. Treatment with DFMO during TCR activation, however, reduces cellular
viability (Figure 19E) and eventually leads to activation of caspase 3/7 expression (Figure
19EF), suggesting that cell death by reduced polyamine production leads to the enrichment of
Tbetdim Eomes hi CD8+ T cells.
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Figure 19: Polyamine Production blockade decreases T-bet-expressing cells but
increases cell death. (A) DFMO is an irreversible inhibitor of ornithine decarboxylase (ODC);
(B) Cell surface expression for activation markers CD25 and CD69 after 24-48 hours exposure
of DFMO; (C-D) Percent of CD8+ T cells expressing transcription factors T-bet and Eomes after
72 hour activation with and without DFMO; (E) Percent of viable cells over time during activation
with and without DFMO; (F) Percent of CD8+ T cells with high Caspase 3/7 activity after 72
hours of DFMO treatment during activation. *p<0.05, **p<0.01, ***p<0.001
Polyamine production is necessary for activated CD8+ T cells to asymmetrically divide
Consistent with other studies using ODC 13 blockade, DFMO-treated CD8+ T cells
displayed a reduced cell trace violet dilution (Figure 20A). Interestingly, this occurs without
impacting S-phase transition as the entire population progresses through the first round of
division. The cell proliferation arrest was reversed by putrescine indicating that the impact of
DFMO is caused by the specific depletion of this metabolite. During early rounds of division
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following TCR stimulation, activated CD8+ T cells undergo a unique process known as
asymmetric cell division (ACD).

Differential expression of CD8 on the cell surface and

differential expression of the transcription factor Myc are hallmarks of this phenotype14.
Specifically, CD8lo/Myc lo CD8+ T cells have decreased glycolytic rates relative to CD8hi/Myc hi T
cells and exhibit a propensity to form long-term anti-viral immunity in vivo in chronic
infections 14,234. Evidence suggests that glutoaminolysis regulates Myc distribution relative to
CD8 cell surface expression14. Given that we have shown that glutamine is the preferred carbon
source of polyamine production (Figure 18E-G), we reasoned that polyamines may be involved
in the ACD process. To more efficiently study this process, polyclonal T cells were derived from
the Myc-eGFP reporter mice in which enhanced GFP is inserted into exon 2 creating an Nterminal EGFP/Myc protein235, and were activated with anti-CD3 and anti-CD28 +/- DFMO. CD8
populations were defined within the first round of division using dilution of CellTrace Violet and
staining with CD8 (Figure 20B). DFMO treatment reduced CD8 cell surface expression during
the first round of division (Figure 20B) compared to control treated cells, which resulted in an
enrichment of CD8lo T cells and a decrease in the CD8hi population (Figure 20C).
The master metabolic regulator Myc is distributed with CD8 cell surface expression
during ACD, such that within the first round of division, CD8 hi cells express higher Myc protein
and CD8lo cells express lower Myc protein14. Interestingly, Myc is a transcriptional activator of
Odc mRNA236 and there is a positive feed-back loop where polyamines regulate the translation
of Myc protein202,237 . DFMO treatment suppressed the average Myc-GFP protein expression in
all activated CD8+ T cells (Figure 20D) consistent to an accumulation of CD8lo/Myc lo cells in the
first round of division. DFMO-treated CD8+ T cells were then divided into CD8hi and CD8lo cells.
Notably, Myc protein expression was decreased in both populations (Figure 20E),
demonstrating that polyamines are required for the distribution of Myc during ACD.
Polyamines control protein translation through the hypusination pathway in which the
aminobutyl group of spermidine is transferred as hypusine to eukaryotic translation initiation
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factor 5A (eIF5A) and becomes hydroxylated to become the active form, hypusinated eIF5A165
(Figure 21A). Hypusinated eIF5A broadly impacts protein translation as an elongation factor,
and the enzymes that direct hypusination of eIF5A are increased in antigen-activated CD8+ T
cells (Figure 21B). The activation of eIF5A can be inhibited by the spermidine mimetic GC7,
which blocks the enzyme responsible for transferring the aminobutyl group to eIF5A (Figure
21A). Similar to treatment of activated CD8+ T cells with DFMO, targeting the hypusination
pathway significantly decreased proliferation in response to TCR stimulation (Figure 21C). Firstgeneration CD8+ T cells treated with GC7, however, had no major alterations in CD8hi and CD8lo
populations (Figure 21D-E). Indeed, first generation CD8+ T cells treated with GC7 had normal
distribution of Myc in addition to the normal distribution of CD8 (Figure 21F). Moreover, GC7
maintained the positive relationship between CD8 and Myc that is disrupted by DFMO (Figure
21G-I). These results suggest that putrescene plays a critical, previously unidentified role, in
differentially distributing Myc and CD8 during ACD independent of other polyamines such as
spermidine which is involved in controlling hypusination of eIF5A. Moreover, this suggests that
DFMO treatment and blockade in polyamine production with PTIs may alter the memory T cell
response during viral infection or cancer immunotherapy.
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Figure 20: Blocking polyamine biosynthesis alters asymmetric division. (A) Average
number of divisions (division index) after 48 hours of antigen activation with and without DFMO
and the addition of 500 M putrescine; (B) Gating strategy to analyze asymmetric cell division;
(C) Percent of CD8hi and CD8lo CD8+ T cells within the first round of division after 48 hours of
DFMO treatment; (D) Total Myc-GFP expression among all CD8+ T cells; (E) Myc-GFP
geometric mean fluorescent intensity (MFI) in first round of division CD8 hi and CD8lo
populations. **p<0.01, ****p<0.0001
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Figure 21: Polyamine-driven asymmetric cell division is independent of hypusinated
eIF5A. (A) Hypusination pathway in which spermidine is used to create dehypusinated eIF5A to
eventually become the activated hypusinated eIF5A; (B) mRNA expression of enzymes in the
hypusination pathway after antigen activation; (C) CellTrace Violet histogram (left) and average
number of divisions (right) after 48 hours of anti-CD3 and anti-CD28 activation; (D-E) CD8hi and
CD8lo populations among the first round of division for CD8 + T cells activated for 48 hours; (F)
Myc-GFP geometric mean fluorescent intensity (MFI) in first round of division CD8 hi and CD8lo
populations; (G-I) MFI of CD8 versus MFI of Myc within the first round of division. *p<0.05,
**p<0.01, ***p<0.001
Inhibition

of

polyamines

decreases

glycolysis

and

increases

oxidative

phosphorylation
To further elucidate which signaling pathways are altered by polyamines, DFMO-treated
activated CD8+ T cells were subjected to RNA-seq analysis.
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These results revealed that

polyamine blockade significantly alters the expression of many genes (Figure 22A). Transcripts
were further analyzed using previously-defined KEGG pathways. Both glycolysis and fatty acid
metabolism pathways are significantly decreased by DFMO treatment (Figure 22B, p=0.016 &
0.001 respectively). Interestingly, we found that cysteine and methionine metabolism and
oxidative phosphorylation (OxPhos) were increased in DFMO-treated T cells, though OxPhos
was not significant (Figure 22B, p=0.011 & 0.194 respectively).
Metabolic changes in activated T cells have downstream effects on effector function so
global metabolomic profiling of DFMO-treated CD8+ T cells was conducted by LC/MS (as
described in Chapter Two). Several metabolites were changed after DFMO treatment including
both amino acids and glycolytic intermediates (Figure 23A). Reductions in glycolysis were
confirmed by the Seahorse SF analyzer where glycolytic rates were suppressed by DFMO
treatment (Figure 23B), consistent with the RNA-seq data. Conversely, the mitochondrial stress
test demonstrated that basal oxygen consumption rates were minimally affected by DFMO
treatment, and that these drug-treated cells have significantly increased spare respiratory
capacity (SRC) after FCCP (Figure 23C). Consistent with higher mitochondrial respiration, an
increase in mitochondrial biomass was observed through mitotracker green staining (Figure
23D).
Next, a modified Seahorse mitochondrial stress test was performed on DFMO-treated
OT-1 CD8+ T cells (Supplemental Figure 23E-H) to acutely suppress glycolysis, glutaminolysis
and fatty acid oxidation in order to define the fuel source contributing to the increased levels of
SRC. Interestingly, acutely blocking glycolysis by injecting 2-deoxyglucose (2-DG) decreased
the SRC of DFMO-treated CD8+ T cells as well as severely decreasing ATP production (Figure
23H-J). This suggests that glucose transport and utilization accounts for the increase in SRC in
DFMO-treated cells. The acute blockade of glutaminolysis by DON also decreased SRC
without impacting ATP production (Figure 23G, I-J). Further, blocking Cpt1a and fatty acid
oxidation by etomoxir had no effect on oxygen consumption or ATP production by CD8+ T cell
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with and without DFMO treatment (Figure 23F, I-J). Therefore, glucose and glutamine fuel the
enhanced SRC of DFMO-treated antigen-activated CD8+ T cells.

Figure 22: RNA-seq analysis of DFMO-treated CD8+ T cells activated for 48 hours. (A) Fold
change in transcription after 48 hours of DFMO treatment as well as p values of individual T
tests; (B) Unsupervised clustering of transcriptional changes with and without DFMO treatment
in KEGG-defined pathways: glycolysis, fatty acid oxidation, cysteine & methionine metabolism
and oxidative phosphorylation.
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Figure 23: DFMO treatment increases the spare-respiratory capacity of antigen activated
CD8+ T cells. (A) Unsupervised clustering of annotated metabolites from a global metabolomics
screening of CD8+ T cells activated and treated with and without DFMO for 48 hours; (B-C)
Seahorse analysis of extracellular acidification (ECAR) and oxygen consumption (OCR) using
the glycolysis rate assay and mitochondrial stress test (MST); (D) Intracellular mitochondrial
biomass as measured by the G-MFI of MitoTracker Green; (E-H) Oxygen consumption rates
meaured by a modified MST in which etomoxir, DON, 2-DG or Seahorse Media were were
injected prior to running the normal MST. (I) Spare respiratory capacity and ATP production as
measured by oxygen consumption demonstrated in E-H. *p<0.05
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Discussion
Here we demonstrate that TCR-specific stimulation increases intracellular polyamine
levels, largely driven by the metabolism of glutamine rather than arginine. Blocking polyamine
production profoundly alters gene expression and metabolic rates of activated CD8 + T cells and
revealed that polyamines play an important role in role in Myc and CD8 distribution during
asymmetric division. The relative distribution of T-bet and Eomes following DFMO treatment
also suggests that the T-box transcription factor balance is tipped toward Eomes. It is still
unclear, however, if balanced T-bet and Eomes expression dictates the ultimate fate of
activated CD8+ T cells although T-bet deficiency favors the generation of central rather than
short-lived effector cells.
Interestingly, our studies demonstrate that putrescine to play a specific and possibly
critical role in asymmetric division. Specifically, DFMO treatment not only increased CD8lo T
cells, but also disrupted the distribution of Myc and CD8 expression during asymmetric cell
division, leading to

(Figure 20B-E, 21G-H) higher percentages of CD8loMyc lo cells which

appears critical for CD8+ T cell fate during chronic viral infection and possibly during anti-tumor
immunity. Similar to DFMO-treated cells, previous studies have demonstrated CD8lo/ Myc lo T
cells have increased oxygen consumption and lower extracellular acidification c ompared to
CD8hiMyc hi.
ACD directs T cell fate. Isolation and adoptive cell transfer of CD8lo/Myc lo cells isolated
during the first round of division display significantly better recall responses in vivo after
vaccination but poor initial viral clearance14. Given that DFMO treatment induces CD8loMyc lo
dominance during the first round of division, polyamine blockade could result in more CD8+ T
cell recall following vaccination. Investigating the role of polyamine production in this setting is
important for understanding the role of polyamine metabolism in CD8+ T cell differentiation and
immunotherapy. For instance, during TIL or CAR-T cell production, the use of DFMO may
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dampen T cell expansion but lead to more persistent memory cells in vivo, which has been
identified as a key barrier to successful CAR-T238,239.
It is notable that glutamine is the primary source of CD8 + T cells’ polyamine production
after TCR stimulation (Figure 18E). Arginine-derived ornithine has been demonstrated in
activated CD4+ T cells, but a competitive isotope tracer experiment like the one presented here
has not been previously published4 4. Glutamine is an amino acid frequently found in low
abundance in the tumor microenvironment. Therefore activated CD8 + T cells’ in the tumor
microenvironment may have reduced polyamine levels. Many cancer cells increase amino acid
metabolism and accumulate or secrete high levels of polyamines in the extracellular milieu240.
Since putrescine has the ability to reverse the proliferative block induced by DFMO on CD8 + T
cells (Figure 19A), it is possible that activated CD8+ T cells may transport excess polyamines to
bypass ODC inhibition. Future studies are required to define the intracellular polyamine levels in
CD8+ T cells in the tumor setting and to define their polyamine transport capability. Polyamine
transport suppression may decrease intracellular polyamine availability and suppress
proliferation.
Metabolomics analysis showed lower glycolytic intermediates following DFMO treatment
in OT-1 T cells (Figure 23A), concordant with a reduced extracellular acidification rate and
reduced expression of the glycolytic enzymes (Figure 23B, 22B). The significant alterations in
gene expression were not due to altered levels of TCR signaling since normal CD69 and CD25
cell surface expression were observed (Figure 18B). Normally, increases in glycolysis occurs
after TCR stimulation, and this increases the rate at which pyruvate is converted into lactate
over the rate that pyruvate is oxidized and shuttled into the mitochondria for use in the TCA
cycle13,80,241-243. Despite these findings, acute inhibition of glycolysis by 2-DG severely
decreased the spare respiratory capacity of DFMO-treated activated CD8+ T cells (Figure 23G,
I-J), suggesting some dependence on the glycolysis. However, 2-DG also inhibits the TCA cycle
and its intermediates 244, and thus it is plausible that DFMO augments the TCA cycle in CD8+ T
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cells, allowing higher ATP production from pyruvate. Intracellular glutamine could also be
converted into more alpha-ketoglutarate to fuel the TCA cycle in the presence of DFMO, given
that one direction for glutamine to be metabolized is blocked. Further studies using isotopically
labeled glutamine and glucose would confirm the effects of polyamine production on the TCA
cycle. The preference for OxPhos observed after DFMO treatment is also consistent with an
abundance of CD8lo/Myc lo populations during ACD.
Collectively, we have identified a crucial metabolic pathway in CD8+ T cells, where
suppression of polyamine biosynthesis alters proliferation, T-bet and Eomes expression and
stimulates mitochondrial SRC and OxPhos. Thus, manipulating the polyamine pathway may be
useful in the setting of immunotherapy. Future studies are required to assess the impact of
polyamines on T cell fate determination.

Methods
Methodology for mouse immune cell isolation, CD3+ T cell and OT-1 CD8+ T cell
activation, flow cytometry, metabolomics, and statistical analysis is the same as in Chapter
Two. Some critical reagents are listed previously in Table 6.
Mouse Husbandry
OT-1 transgenic mice160 and Myc-eGFP mice235 were obtained from Jackson Lab.
Stocks were maintained and bred at the H. Lee Moffitt Cancer Center and Research Institute
under approved protocols by the Institutional Animal Care and Use Committee.
Isotope analysis
Activated OT-1 T cells were washing in DMEM containing high glucose and no arginine,
glutamine or lysine. Cells were then labeled with either 2 mM 13C-Arginine (Cambridge Isotopes,
fully labeled) and 2 mM 12C-Glutamine (Gibco) or 2mM 13C- Glutamine (Cambridge Isotopes,
fully labeled) and 2 mM 12C- Arginine (Sigma Aldrich) for 3 or 6 hours at 37°C at which time
media was removed from the cells and pellets were immediately placed on ice.
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For targeted isotope tracer analysis, 5 μL of each sample was analyzed using an ultrahigh performance liquid chromatograph (Vanquish, ThermoFisher Scientific, San Jose, CA)
interfaced with a QExactive HF mass spectrometer (ThermoFisher Scientific, San Jose, CA)
using full MS and selected ion monitoring (SIM) for five labeled and unlabeled endogenous
metabolites; arginine, putrescine, ornithine, spermine and spermidine. Samples were separated
using an Accucore reversed phase C18 column (27826-153030, 2.1 mm ID x 100 mm length,
2.6 µm particle size, ThermoFisher Scientific) at 350 μL/min. A gradient starting at 20% B was
held for 2 minutes, then ramped from 20% B to 50% B from 2 to 4 minutes and from 50% B to
80% B from 4 to 6 minutes; followed by re-equilibration over 3 minutes, for a total of 9 minutes
for each experiment. Solvent A was 100% HPLC grade water (LC365-4, Burdick & Jackson,
Honeywell, Muskegon, MI) containing 0.05% Heptafluorobutyric acid (LC6206, HFBA,
Proteomics Grade, ProteoChem, Hurricane, UT), and solvent B was 100% HPLC grade
methanol (LC230-4, Burdick & Jackson, Honeywell, Muskegon, MI) containing 0.05%
Heptafluorobutyric acid (LC6206, HFBA, Proteomics Grade, ProteoChem, Hurricane, UT);
HFBA was used as counter-ion to enable analysis of the polyamines 245.

Samples were

analyzed in positive ion mode using an ESI voltage of 3.5 kV. Mass spectrometry instrument
parameters for SIM included the following: resolution 70,000; isolation window width 1.0 m/z ;
AGC target 2e5; maximum IT 200 ms; an inclusion list containing the m/z for each labelled and
unlabeled targeted metabolite and a scheduled time window for metabolite elution. Peak heights
for unlabeled metabolites and 13C-labeled metabolites were extracted from the chromatograms
using Xcalibur Quan Browser (version 3.0.63, ThermoFisher Scientific, San Jose, CA).
Metabolic Analyses
Seahorse metabolic assays were conducted using antigen-activated OT-1 CD8+ T cells
plated in Seahorse base medium supplemented with 6 mM glucose and 1 mM glutamine at 10 5
T cells per well in a 96-well Seahorse plate. Mitochondrial stress tests (MST) and glycolytic rate
assays were used as per manufacturer’s protocol or 4 μM etomoxir, 100 μM DON, or 100 mM 278

deoxyglucose was injected prior to running the MST. Extracellular acidification and oxygen
consumption rates were analyzed using Wave Software.
Quantitative PCR Analysis
Cell pellet storage, RNA isolation and cDNA conversion were all conducted as in
Chapter Two. All RNA was quantified by Sybr Green. Slc7a1, Slc38a1, Slc38a2, Odc1, Oat,
Srm, Sms, and B2M sequences are listed previously in Table 5. Dhps, Dohh, Slc1a5, Slc3a2,
Slc7a2, Slc7a5, Slc7a6, Slc7a11, and Aldh18a1 sequences are listed below in Table 7.
Table 7: RT-PCR Primer Sequences

RNA-seq
Cell pellets were harvested and kept in Buffer RLT at -80°C until use. RNA was isolated
using manufacturer’s protocol (AllPrep DNA/RNA Mini Kit, Qiagen) with the addition of DNase.
RNA-sequencing was run in the Genomics Core and data processing was done with the
Bioinformatics Core, both at Moffitt Cancer Center.
For KEGG analysis, genesets were downloaded from Broad Institute's MSigDB
(http://software.broadinstitute.org/gsea/msigdb/collections.jsp) and KEGG gene sets were

79

further used for the analysis. Genes were equally weighted with a coefficient of 1 in each gene
set. A gene set score was calculated for each sample by taking the sum of each genes z-score
if it appeared in the gene set of interest. Upon gene set scoring, a student's t-test was used to
statistically determine the most significantly altered gene sets between treatment. Heat maps
display the z-score of the genes within the gene set of interest on a range from -3 to 3 and are
hierarchically clustered using the Ward linkage method and Euclidean distance metric.
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CHAPTER FOUR:
T-REGULATORY SUBPOPULATIONS ASSOCIATED WITH RECENT ULT RAVIOLET
RADIATION EXPOSURE IN A SKIN CANCER SCREENING COHORT
A note to the reader: this chapter has been previously published in a research article in
Journal of Immunology, Hesterberg et al 20182.
Introduction
This is the first epidemiological study to investigate the association between UVR and
immune response mediated by Treg cells among a cohort of individuals undergoing routine skin
cancer screening exams using a quantitative, spectrophotometer-based measure of UVR.
Circulating Tregs were characterized using flow cytometry of cells in the peripheral blood, as
defined previously on the basis of FoxP3, CD4, and CD25 expression145,246. The percent of total
circulating conventional T cells and Tregs were quantified, in addition to specific Treg cell
subpopulations, defined by the expression of CD45RA and CD27 markers 132,134,145 and markers
associated with bidirectional trafficking between lymph node and skin 247,248 , including cutaneous
lymphocyte-associated antigen (CLA) and the chemokine receptor CCR4132,134,142,145,153,247,249
and graded expression levels of FoxP324 6. We hypothesized that UVR would be associated with
higher levels of a circulating Treg cell population or a higher number of total Treg cells in this
cohort.

Results
Characterization of Tregs associated with UV exposure
During the first year of recruitment (July 2014-July 2015), 917 individuals were
approached, of whom 448 (49%) consented to participate. No significant differences were
observed between study participants and individuals who declined participation with respect to
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sex (p=0.17) or age (p=0.16). Participants were asked to complete a web-based questionnaire,
including demographic and skin cancer risk factor information. In addition, blood samples and
skin pigmentation measurements were obtained from each participant. Blood samples were
collected from 409 patients, of which 378 samples were found to have sufficient numbers of
viable cells available for flow cytometry. Individuals with a pathologically confirmed NMSC at
baseline (n=23) or missing skin pigmentation readings (n=5) were excluded. Therefore,
analyses included 350 individuals with complete information on both Tregs and UVR exposure.
Skin pigmentation readings were used as a marker of recent UVR exposure and for
natural skin tone, consistent with previous epidemiologic studies 150,151. Males had significantly
higher spectrophotometer readings (14.61 ± 3.12) than females (9.37 ± 2.62, p<0.0001),
whereas there was no association with age (p=0.81).
PBMC samples were analyzed by flow cytometry, as shown in Figure 24145. First, CD8+
T cells and CD4+ T cells of CD3+ lymphocytes were identified followed by CD4+ T cells which
were further defined as CD25-FoxP3- conventional T helper cells (Th CD4) and total
CD25+FoxP3+ Treg cells. Reduced expression of CD127 on CD25+FoxP3+Treg cells was
confirmed, as described previously, but was not included in this analysis (data not shown)145.
Recent UVR exposure was plotted against each population of T cells (Figure 25). The
proportion of CD8 (33 ± 14.4), Th CD4 (66.1 ± 14.6), and total Treg cells (4.29 ± 2.15) were
within normal range for peripheral blood of healthy individuals 145. CD8+ T cells (r=0.03, p=0.56),
Th CD4+ T cells (r=0.09, p=0.09), and total percent of Tregs among all CD4+ T cells (r=-0.03,
p=0.54) did not correlate with UV exposure (Figure 25A-C).
In addition to these populations, functionally distinct Treg subpopulations were
examined, as defined in Figure 24B-F. Four phenotypically distinct Treg cell populations were
evident by flow cytometry with the vast majority (75.0 % ± 10.5) displaying a CD45RA-/CD27+
central memory phenotype, as described previously14 5. CLA+ and CCR4hi Treg cells did not
express CD45RA, consistent with prior antigen engagement, but consisted of both CD27 + and
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CD27- subpopulations (Figure 24E-F), similar to conventional Th CD4+ T cells (Figure 26C-D).
The CD45RA-/CD27- (activated, effector memory) Treg (Figure 25G), CLA+ Treg (Figure 25F)
and CCR4hi Treg cells (Figure 25I) were positively correlated with recent UVR exposure among
all individuals (r=0.19, p<0.01; r=0.13, p=0.01; r=0.17, p<0.01; respectively). In contrast,
CD45RA+/CD27+ Tregs (i.e., naïve) showed a less pronounced, negative correlation (r=-0.11,
p=0.03) (Figure 25D) indicating that these specific Treg subsets, not total Tregs or conventional
T cells, correlated with recent UVR exposure. Of note, no self-reported measures of past UVR
exposures or sun susceptibility factors were associated with these four Treg populations (Table
8).
To further explore the Treg populations and their association to UVR, CD4 + T cells were
also segregated into 6 populations defined previously246 using CD45RA, CD25 and levels of
FoxP3 (Figure 24G-H) with Groups I-III all expressing FoxP3 consistent with having a Treg
phenotype

246

. Group II (CD45RA-CD25+++FoxP3hi) and Group I (CD45RA+CD25++FoxP3l o) are

functionally suppressive while Group III having a CD45RA-CD25++FoxP3lo phenotype are nonsuppressive, but are capable of secreting cytokines. Although the CD45RA-/CD27- FoxP3
population showed an association to UVR exposure, no association was observed with the
CD45RA- Tregs defined as Group II or Group III (Figure 24K and 24L, respectively).
Interestingly, Group I Tregs were negatively associated with recent UVR exposure (r=-0.16,
p<0.01) (Figure 25J).
To further define the characteristics of the Tregs and conventional T cells through
association studies, a correlation matrix was prepared for all T cell populations identified. Group
I and Group II Treg populations were highly correlated with total Tregs , but were not associated
with Tregs defined by other surface markers including CD27, CLA and CCR4 (Figure 27).
Indeed, we found there is a high positive correlation between CD45RA+/CD27+ Tregs “naïve
Tregs” and the Group I population “resting Tregs” (Figure 27). These results are consistent
with the negative association between both Group I and CD45RA+/CD27+ Treg populations.
83

Moreover, overlays of the flow cytometry expression patterns revealed CD27, CLA and CCR4
are represented throughout Group II-IV populations (Figure 24I) indicating these markers
further differentiate Tregs. Gating on such populations within Group II-III may be necessary to
observe correlations between Tregs defined by this strategy and recent UVR exposure.

Figure 24: Flow cytometry gating strategy for Treg cell analysis. PBMCs were gated first on
viability and on CD3 and CD4 positivity. (A-D) (A) CD4+ Treg cells were defined by high
expression of CD25 and intracellular Foxp3 and conventional CD4+ T cells (Th CD4) were
defined by low expression of CD25 and Foxp3. (B) Tregs were then analyzed for CD45RA and
CD27 expression and populations were defined by dual or single expression. (C-F) CLA and
CCR4 expression was also analyzed among Treg cells. CLA and CCR4 positive Treg cells were
also confirmed to be CD45RA negative with mixed expression of CD27. (G-I) (E) Six groups of
CD4+ T cells were defined by CD45RA positivity and varying CD25 expression. (H) Each
population was analyzed for FoxP3 expression. (I) Distribution of these populations were
analyzed in CD45RA-/CD27+ CM.Treg cells, CD45RA-/CD27- E.Treg cells, CLA+ Treg cells
and CCR4hi Treg cells as defined in (B-D).
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Figure 25: T cell populations in correlation with recent UV exposure among 350
individuals undergoing skin cancer screening. Correlations between Treg cells and UVR
were calculated using Spearman’s rank, and a trend line was created to visualize the
associations. (A-C) Scatterplot of spectrophotometer reading and CD8, Th CD4, total Treg cells.
(D-I) Scatterplot of spectrophotometer reading and phenotypes of Tregs defined in Figure 23A.
(J-L) Scatterplot of spectrophotometer reading and Group I, II, and III T (Treg) cell phenotypes
defined in Figure 23G.
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Table 8: Circulating regulatory T (Treg) cell phenotypes and questionnaire factors.

1

SD=Standard deviation
p-values were calculated using linear regression, adjusted for age (categorical) and sex with
transformed Treg data as follows: CD45RA+/CD27+ Treg (8th root), CD45RA-/CD27- Treg (4th
root), CLA+ Treg and CCR4hi Treg (4th power).
3
Natural skin tone based on median spectrophotometer readings in the axilla, as defined in
Methods.
2
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Figure 26: Flow cytometry gating strategy controls in reference to Figure 23. PBMCs were
gated first on viability and on CD3 and CD4 positivity. ( A-B) CD25 and Foxp3 flourescenceminos-one (FMO) control samples used to define CD25+ Foxp3 + Treg populations, (C-D) CLA+
and CCR4hi Th CD4+ T cells were confirmed to be CD45RA- with mixed expression of CD27, (EF) CD45RA and CD25 FMO control samples used to defined Group I-VI.
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Figure 27: Spearman rank correlation matrix for T cell populations among 350 skin
cancer screening patients. Spearman correlation coefficients (rho) are presented for all T cell
populations. The matrix cells are shaded only if they are significantly correlated at p<0.05 level.
Red shading represents a positive correlation whereas blue shading represents a negative
correlation.
Natural skin tone represents an effect modifier of the UVR and Treg association
Previous studies of nevus development in children have reported effect modification of
UVR-associated physiologic effects by one’s natural skin tone 25 0,251.

To test whether the

associations between UVR and Treg cell phenotypes differed by natural skin tone , we stratified
our analysis by lighter versus darker skin tone, based on the median value of the
spectrophotometer readings of the sun-unexposed axilla. Interestingly, a significant positive
correlation between recent UVR and the proportion of activated, effector memory CD45RA/CD27- Treg cells (r=0.30, p<0.01) was observed only in individuals of lighter skin (Figure 28). In
contrast, CD45RA+/CD27+ naïve Treg population negatively correlated with recent UVR
exposure in lighter-skinned individuals, though the trend was not as striking as the association
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with increased CD45RA-/CD27- Tregs (Figure 28). The positive correlation between UVR and
CLA+ Treg cells was also restricted to the lighter-skinned individuals (r=0.15, p=0.04). However,
UVR and CCR4hi Tregs were positively correlated among both darker-skinned (r=0.18, p=0.02)
and lighter-skinned individuals (r=0.14, p=0.06), with the former being statistically significant.
These results suggest that individuals with a lighter natural skin tone may be at higher risk for
UVR-induced changes in Treg cells.

89

Figure 28: Effect modification by natural skin tone. Scatterplot of spectrophotometer
readings and Treg cell subsets that were found to have significant associations with UVR after
stratification by natural skin tone as defined by median spectrophotometer readings of sununexposed underside of the upper arm (i.e. the axilla). Correlations between Treg cells and
UVR were calculated using Spearman’s rank, and a trend line was created to visualize the
associations.
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Demographics are associated with Tregs
Associations between demographic factors and Treg subpopulations, including naïve
CD45RA+/CD27+, activated effector CD45RA-/CD27-, CLA+, and CCR4hi Tregs (based on
results shown in Figure 24), are presented in Table 9. A statistically significant inverse trend
was observed between age and naïve CD45RA+/CD27+ Tregs (p-trend=<0.01). Conversely,
CD45RA-/CD27- Treg cells were positively associated with age (p-trend=0.04). This is similar to
the expected loss of conventional naïve T cells due to thymic involution and shown previously
for Treg cells in mice146,252-254. Significant positive trends were also observed between age and
the two skin migratory Treg cells, the CLA+ (p-trend=0.02) and CCR4hi (p-trend=0.01) Treg
populations (Table 9).
Interestingly, Treg populations differed significantly by sex after adjusting for age,
including higher numbers of CD45RA-/CD27- Tregs in males (14.5 ± 6.8 in males versus mean
13.0 ± 7.0 in females, p=0.02), higher CLA+ Tregs in males (59.3 ± 10.7 in males versus mean
56.0 ± 11.3 in females, p=0.01), and higher CCR4hi Tregs in males (84.5 ± 8.4 in males versus
82.8 ± 8.4 in females, p<0.01). Race was also associated with CD45RA-/CD27- Tregs (mean
13.5 ± 6.8 in white versus mean 19.9 ± 9.6 in others, p<0.01). Ethnicity was not associated with
Treg populations (Table 9). Treg cells defined as Group I-III (Figure 24D) were also analyzed
by demographic information. No association was found among Group I-III populations with age,
sex or ethnicity. Group II populations were significantly associated with race with white
participants having higher numbers (Table 10). This finding is consistent with a the significant
racial difference observed for the distinct Treg subpopulation defined by CD45RA-/CD27expression, which was strongly

negatively correlated with age, independent of Group I-III

distribution (Figure 27).
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Table 9: Circulating regulatory T (Treg) cell phenotypes and demographic characteristics.

1

SD=standard deviation
Coefficients and p-values were calculated using linear regression, adjusted for age CD45RA- (categorical) and sex with transformed
Treg data as follows: CD45RA+/CD27+ Treg (8th root), /CD27- Treg (4th root), CLA+ Treg and CCR4hi Treg (4th power)
3
Coefficient and p-trend was calculated using linear regression with continuous age, presented in years, and adjusted for sex, with
transformed Treg data
4
p-values were calculated using linear regression adjusted for age (categorical)
2
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Table 10: Circulating Group I-III regulatory T (Treg) cell phenotypes and demographic
characteristics.

1

SD=standard deviation
p-values were calculated using linear regression, adjusted for age (categorical) and sex with
transformed Treg data: Group I (8th root), Group II (4th root), Group III (4th root)
3
p-trend was calculated using linear regression with continuous age, presented in years, and
adjusted for sex
4
p-values were calculated using linear regression adjusted for age (categorical)
2

Recent UVR and Tregs are independently associated
Associations between recent UVR and quartiles of circulating Treg cells are presented in
Table 11. We observed a positive trend between recent UVR and quartiles of CD45RA-/CD27Treg in all individuals (p-trend=0.02) (Table 11). After stratification by natural skin tone, the
UVR association with CD45RA-/CD27- Treg cells was particularly pronounced among lighterskinned individuals, with each unit increase in spectrophotometer readings associated with a
32% increase in odds of being in the uppermost versus lowermost quartile of CD45RA-/CD27Tregs (OR=1.32, 95% CI=1.12-1.61), after adjustment for age and sex. The strength of this
association supports its biological relevance. Interestingly, we observed a significant inverse
trend with recent UVR exposure and quartiles of CD45RA- /CD27+ Treg among all individuals (p93

trend=0.04) and lighter-skinned individuals (p-trend=0.01), but not among darker-skinned
individuals (p-trend=0.22). Among darker-skinned individuals, UVR exposure was significantly
lower among those in the second and third quartiles of CD45RA+/CD27- Treg compared to the
first, although no clear trend was observed, taking into account the highest quartile (ptrend=0.11). No associations were observed between UVR exposure and quartiles of total Treg,
CLA+ Treg and CCR4hi Treg, overall or after stratification by natural skin tone (Table 12).
Table 11: Quartiles of circulating regulatory T (Treg) cell subpopulations and UV
spectrophotometer readings among all 350 patients undergoing skin cancer screening.

1

Natural skin tone based on median spectrophotometer readings in sun-unexposed underside of
the upper arm, as described in Methods
2
Tregs were categorized into quartiles using the following cut-offs:
CD45RA+/CD27+ Treg: 4.89-8.34-13.5
CD45RA-/CD27+ Treg: 71.43-76.9-80.9
CD45RA-/CD27- Treg: 8.44-12.25-17.4
CD45RA+/CD27- Treg: 0.12-0.43-1.03
3
SD=standard deviation
4
Odds ratios (OR) and 95% confidence intervals (CI) for average spectrophotometer readings
were calculated using logistic regression, comparing each risk group to the reference group Q1
5
p-trend was calculated using ordinal logistic regression
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Table 12: Quartiles of total Tregs, CLA+ and CCR4hi Tregs and UV spectrophotometer
readings in all individuals and stratified by natural skin tone.

1

Natural skin tone based on median spectrophotometer readings in the axilla, as defined in
Materials and Methods.
2
Tregs were categorized into quartiles using cut-offs as the following:
Total Treg: 2.73-4.01-5.28, CLA+ Treg: 50-57.8-65.58, CCR4hi Treg: 77.9-84.2-89.2
3
SD=standard deviation
4
Odds ratios (OR) and 95% confidence intervals (CI) for average spectrophotometer reading
were calculated using logistic regression, comparing each risk group to the reference group Q1
5
p-trend was calculated using ordinal logistic regression

Discussion
NMSC is the most common malignancy in the United States with older age (> 60 years)
representing an important risk factor255. This is the first epidemiologic study of recent UVR
exposure and Tregs in a population of individuals ages 60 years and older at high risk for
NMSC. In 350 individuals undergoing skin cancer screening, recent UVR exposure was
positively associated with activated, effector memory CD45RA-/CD27- Treg cells, whereas an
inverse association was observed between recent UVR and CD45RA-/CD27+ Treg cells.
Furthermore, these associations were specific to lighter-skinned individuals. No associations
were observed between recent UVR exposure and the total percentage of Tregs relative to
conventional CD4+ or CD8+ T cells.
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To the best of our knowledge, previous findings of UVR-related changes in Treg cells
have been exclusively reported for in vitro studies or in mouse models in vivo, where subsets of
T cells were not specifically studied138,247,256 .

Tregs are largely thought of as migratory

populations both in circulation and in lymph nodes, but many are retained in cutaneous tissue
where they curb autoimmune diseases of the skin, contribute to tumor progression, allergic
responses, and microbial immunity257,258. In cutaneous tissues, over representation or increased
suppressive functions of Treg cells may contribute to immune evasion and development of skin
cancer.
We have reported previously that CD45RA-/CD27- Treg cells represent a more
suppressive subset on a per cell basis in T cell suppression assays 145.

Due to the similarity

between CD45RA-/CD27- Tregs and conventional T effector cells, these cells were termed
effector memory or TregE M cells. Down regulation of CD45RA and CD27 is aligned with acute
antigen activation in the context of MHC class II, which in the case of Tregs , is largely induced
by stimulatory autoantigens 259- 261. This precise Treg subset was also expanded in a higher risk
cohort of patients with a premalignant human disease MDS characterized by a high rate of
leukemia transformation145. In this disease, the total number of Tregs increases during later
stages of leukemia progression suggesting that an activation-associated phenotypic change and
expansion occur at different points of the disease suggesting that antigen activation may
precede the accumulation of Tregs as a whole262,263. Collectively, our results show an increase
in the CD45RA-/CD27- Tregs in association with UVR exposure, which may occur through local
tissue damage and antigen release. This increase is in tandem to low UV exposure in
individuals with higher levels of naive CD45RA+/CD27+ Tregs.
Alternative gating strategies on CD4 T cells by CD25 and CD45RA to define Tregs,
rather than by FoxP3 and CD25, resulted in no significant findings among this cohort (Figure
24G-H, 25K-L, Table 9). These populations have been previously shown to be phenotypically
distinct in which CD45RA-CD25+++ CD4+ cells, defined as Group II, exhibit more repressive
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activity on conventional T cells than other Treg populations 246. Indeed, these populations
expressed the highest intracellular FoxP3 expression in the cohort presented here, but no
association was found with recent UVR exposure. This population correlated with populations of
total Tregs defined by FoxP3 and CD25, which also showed no correlation with recent UVR
exposure. Given that CD45RA-/CD27- Tregs were found to be present within groups II, III, and
IV, loss of CD27 could contribute to a distinct functional attribute with clinically-relevance to
UVR exposure. Analysis of this process could yield a better understanding of Treg activity in
response to UVR exposure.
Two skin-homing receptors were also measured on Treg cells in the context of UVR,
chemokine receptor CCR4 and CLA143,264. CLA is a carbohydrate epitope induced by the alpha
1,3-fucosyltransferase VII gene and by cytokines and antigen stimulation26 5-267, which is
consistent with higher CD45RA-/CD27- Treg cells. In our data set, all CLA+ cells lacked CD45RA
expression confirming that these are activated Treg cells (Figure 24C).

Recently, CLA

expression on the Treg cell surface was shown to occur after exposure to nitric oxide, a
chemical that is released into the skin upon UVR exposure 264. CCR4 is another skin-associated
T cell marker that has been shown to increase following UVB exposure in mice suggesting that
not only are Tregs activated, but that they are stimulated to express both homing receptors
significant for infiltration into cutaneous tissues 143,268. Most studies suggest that Tregs can
migrate from lymph nodes to skin and then re-enter the circulation268. Transcriptional signatures
and

phenotypes

suggest

that

the migratory

versus

resident

populations

can

be

distinguished257,258. However, conjoined parabiotic surgery of two mice that share the same
vasculature compartment showed that there are T cells in the skin epidermis that do not
equilibrate through blood and are permanently resident in skin 269-2 72. Since many resident Treg
cells remain in the dermis and do not recirculate after activation and migration to skin, Treg cells
may accumulate through repeated sun exposure; a well-defined risk factor for skin cancer 273,274.
While positive correlations were observed between UV exposure and CLA+ and CCR4hi Tregs,
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after adjusting for age and sex these associations were no longer statistically significant
indicating that the strongest independent marker is the accumulation of CD45RA-/CD27- Treg
cells. While it is difficult to delineate the origins of tissue resident cells, future studies are
needed to define whether UVR contributes to the population of tissue resident memory Treg
cells in human skin.
Although several mechanisms control the suppressive functions of Treg cells, UV
promotes IL-10 secretion and reportedly exert suppressive activity largely through IL-10
production and express the glucocorticoid-induced TNF family-related receptor (GITR)275-27 7. In
cancer studies, engagement of GITR with agonistic antibodies potentiates anti-tumor immunity
by destabilizing FoxP3 expression and reducing Treg cells 278. Given that studies have shown
that adoptively transferred UV-activated Tregs into host mice suppress tumor-immune
responses, CD4+ T cell proliferation and contact hypersensitivity276,279- 281, it is likely that UV
exposure increases the suppressive activity of Tregs through antigen activation. This is
congruent with the data reported here in that distribution of total Tregs is not associated with
recent UV exposure (Figure 25C, Table 8). The mechanism for both Treg expansion and
increased suppressive activity has often pointed to the UV-vitamin D production axis

282

. Vitamin

D is both acquired through the diet and through activation of the first synthesis step by radiation
in the UVB range28 2. Topical application of Vitamin D’s active form increases the suppressive
activity of Treg cells 283 and causes comparable effects to UVB radiation in mice. This method for
UV-induced immune suppression is controversial given that Vitamin D receptor knockout mice
are still susceptible to UV-activated Treg cells 284. Furthermore, there are reports that Vitamin D
receptor is not highly expressed in mouse FoxP3+CD4+ Treg cells, but there is an inverse
relationship between VDR-dependent signaling and FoxP3 regulation28 5-289. Vitamin D
production by UVB exposure is particularly high in lighter-skinned individuals, potentially due to
the protectiveness of melanin in individuals with natural dark skin 28 8,290-29 2, which may explain
the more pronounced associations between recent UVR exposure and Treg cells among lighter98

skinned individuals in our cohort. Given the controversial evidence for vitamin D and its role in
UV-induced immune suppression, investigation of vitamin D or vitamin D receptors in the
context of UVR exposure and Treg cells is an important future step.
The cross-sectional nature of this analysis cannot establish the presence of UVR
exposure prior to measurement of Treg cells, although the UVR-associated changes in skin
pigmentation had to have occurred as a result of exposure prior to the time of blood draw. The
exact timing of UVR exposure is unknown, and therefore, the temporal relationship between
UVR exposure and associated changes in circulating Treg cells require further investigation. In
mouse studies, UVB-induced Treg cell activation in skin lasted for two weeks after exposure
and then later contributed to expansion of these cells in the peripheral blood2 93. Some previous
studies of UVR exposure and immune-related conditions have relied on self-report of sun
exposures and ecologic measures, such as latitude, to estimate UVR exposure 147,149,150,294.
Other studies have demonstrated that Treg cell populations are altered with UVR exposure in a
small cohort of patients presenting with autoimmune disorders 151,154, including one such study
that demonstrated that activated CD45RA- Treg cells are increased in psoriasis patients with
recent UV exposure152. Our study builds upon these findings, suggesting that Treg cell
activation occurs with recent UVR in this cohort.
The spectrophotometer readings used in the present study provide an objective and
quantitative measure of recent UVR exposure. Future analysis of this prospective cohort will
focus on the associations between baseline UVR exposure, Treg cells and subsequent
development of NMSC. Here, we report the first quantitative UVR exposure study associated
with subpopulations of Treg cells in peripheral blood.

Future studies are necessary to

understand if UVR leads to the accumulation of tissue resident Treg cell populations and
whether that in turn contributes to carcinogenesis. Additionally, our study reports differences in
Treg cell subpopulations by age, sex and race with potential importance in other immunerelated diseases.
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Methods
Study design and population
Cross-sectional, baseline data from participants enrolled in the first year of the Viruses
and Skin Cancer (VIRUSCAN) Study, an ongoing, four-year prospective cohort study of UVR,
cutaneous viral infections and skin cancer being conducted at the Moffitt Cancer Center, were
used for the current analysis. Individuals undergoing routine skin cancer screening exams at
the University of South Florida Dermatology Clinic (USFDC) were eligible for the study if they
were at least 60 years of age and had not had both a previous SCC and BCC. At the time of
study enrollment, participants underwent a total body skin examination, and suspicious lesions
were biopsied as a part of routine clinical care. Study participants with a pathologically
confirmed NMSC at baseline were excluded. Questionnaire data, peripheral blood samples and
skin pigmentation measurements were also required at study entry. Individuals that failed to
complete these study-related activities were excluded from the analysis. The study was
approved by the USF Institutional Review board, and all patients provided written informed
consent at the time of enrollment.
Spectrophotometer data collection
Skin pigmentation readings were obtained using a spectrophotometer (CM-600D, Konica
Minolta Sensing Americas, Inc.) with Spectra Magic NX Lite USB Ver. 2.5 software, using the
specular component included (SCI) mode of the instrument which minimizes the influence of the
gloss and texture of the skin on skin pigmentation readings, as described previously

295,296

. The

instrument was calibrated against a white tile each morning, per manufacturer guidelines. The
spectrophotometer readings were obtained by study personnel at the initial study visit when
blood samples were collected. This instrument measures color on three different axes: lightness
(L) on a scale of 0 (black) to 100 (white), axis “a”, indicating color within the red-green range,
and axis “b”, measuring color within the yellow-blue range, with increasing values on a and b
axes indicating saturation of color 297 . Natural skin tone was assessed using spectrophotometer
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readings of the sun-unexposed underside of the upper arm (i.e. the axilla). The degree of recent
tanning in response to recent UVR exposure was measured by calculating the difference
between the color readings (delta E*ab) on an area of sun-exposed skin (top of the forearm or
forehead) and the axilla. Three readings were obtained at each anatomic site, and the average
values were recorded.

A strong, intra-individual correlation was observed between

spectrophotometer readings obtained at the forearm and forehead (r=0.6079; p<2.2x10 -16)
(Figure 29). Therefore, the average of these two values was used as the single measurement
of recent UVR exposure.

Figure 29: Spectrophotometer readings between forearm and forehead. Intra-Individual
correlation between spectrophotometer readings obtained at the forearm and forehead among
350 skin cancer screening patients enrolled in year 1 of the VIRUSCAN study. *The p-value was
calculated using Spearman correlation, with correlation coefficient rho=0.6079.
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Blood collection and flow cytometry data acquisition and analysis
Blood samples were collected in three 10 ml heparin sodium containing blood collection
tubes. Samples were processed for isolation of peripheral blood mononuclear cells (PBMCs) by
Ficoll-Hypaque centrifugation using 10-20 ml of Lymphocyte Separation Media (Ficoll)
according to manufacturer guidelines (Amersham Pharma Biotch, Piscataway, NJ). Freezing
medium (10% DMSO, 90% FBS) was used to viably freeze PBMCs in preparation of the future
cytometry analysis. Frozen PBMCs stored in liquid nitrogen were thawed on ice and placed into
1 mL phosphate buffered saline (PBS). Approximately 106 PBMCs were first labeled with the
viability dye Ghost Dye Red 780 (1µL, Tonbo Bioscience) for 20-30 minutes at room
temperature to exclude dead cells from the analysis. PBMCs were then treated with 1µL FcR
receptor blocking reagent (Miltenyi) and labeled with antibodies to detect the following cell
surface antigens: anti-CD3-APC, anti-CD45RA-PerCPCy5.5 (Tonbo Bioscience), anti-CD4BV785, anti-CCR4-BV421, anti-CLA-FITC, PD-1-PE (Biolegend), anti-CD25-BUV395 (BD
Horizon) and anti-CD27-BUV737 (BD Horizon) using 1µL each and for 30 minutes at 4° C.
Cells were fixed with a FoxP3/Transcription Factor Staining Buffer Set (ThermoFisher Scientific)
according to the manufacturer’s protocol and labeled with 5µL FoxP3-PEDazzle594 (Biolegend)
for 30 minutes.
After staining and fixation, cell populations were analyzed within 24 hours on a BD LSRII
flow cytometry instrument (BD Biosciences) using the gating strategy defined in Figure 24 and
Figure 26 and quantified using FlowJo v9 (FlowJo, LLC). The PBMC samples from all patients
were thawed and evaluated for viability. Those with less than 1.0x10 5 viable lymphocytes were
excluded from the final data analysis (n=31). In samples included in the analysis, 3.1x10 5 ±
2.2x105 viable cells were present. Samples were evaluated for CD8+ T cells and CD4+ T cells of
CD3+ lymphocytes. CD4+ T cells were further defined by CD25-FoxP3 - conventional T helper
cells (Th CD4) and total CD25+FoxP3+ Treg and Treg cell subpopulations: CD45RA+/CD27+
(naïve) Treg cells, CD45RA-/CD27- (activated, effector memory) Treg cells (ie, equivalent to
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conventional T-effector cells), CD45RA+ /CD27- (terminal memory) Treg cells (ie, equivalent to
conventional T cells with an exhausted phenotype), CD45RA-/CD27+ (central memory) Treg
cells, cutaneous lymphocyte-associated antigen (CLA) CLA+ (skin migratory) Treg cells, and
chemokine

receptor

132,134,142,145,153,247,24 9

CCR4hi

(skin

migratory)

Treg

cells,

as

previously

described

. All population data is described as a frequency of the parent population. In

addition to the described gating strategy, CD4+ T cells samples were also divided into six
populations according to Miyara et al

2 46

(Figure 24D) to define CD45RA-CD25++FoxP3lo as

resting Treg cells (Group I), CD45RA-CD25+++FoxP3hi (Group II) as activated Treg cells, and
defined CD45RA-CD25++ FoxP3lo (Group III) as nonsuppressive Treg cells.
All gating strategies were confirmed by use of fluorescence-minus-one (FMO) control
samples in which cells are stained with all colors except the antibody noted (Figure 26A-B, EF).
Statistical Methods
Correlations between Treg cells and UVR were calculated using Spearman’s rank, and a
trend line was created to visualize the associations. The correlations between T cell populations
were described using Spearman’s rank correlation coefficient. Additionally, given that previous
studies have reported effect modification of UVR-associated physiologic effects by one’s natural
skin tone250,251 analysis by lighter versus darker skin tone was performed, based on the median
value of the spectrophotometer readings of the sun-unexposed axilla, to investigate whether the
associations between UVR and Treg cell phenotypes differed by natural skin tone. Linear
regression was used to examine the associations between baseline characteristics and Treg
cell phenotypes, adjusted for age and sex. Differences in UVR by sex and age were examined
using the Wilcoxon rank sum test and Spearman correlation, respectively. Logistic regression
was used to calculate odds ratios (OR’s) and 95% confidence intervals (CI’s) to estimate the
associations between recent UVR exposure and quartiles of the Treg cell phenotypes, adjusted
for age and sex. Quartiles were used to account for the possible non-linear relationship between
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Treg cells and recent UVR and to avoid use of data transformation within the multivariate
models. Statistical analysis was conducted using R, version 3.3.2 (R Foundation for Statistical
Computing, Vienna Austria).
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CHAPTER FIVE:
IMPLICATIONS AND FUTURE PERSPECTIVES

The work presented here increases the understanding of the role of glutamine metabolic
pathways in CD8+ T cells, a negative immune regulator, Cereblon (CRBN) of MYC, ERK, and
glutamine metabolism, and suppressive regulatory T cell (Treg) populations that are susceptible
to expansion with UV exposure. These findings lay the groundwork for exciting future studies.
Polyamine

metabolism

regulates

oxidative

phosphorylation,

mitochondria,

and

asymmetric division in activated CD8+ T cells, having large implications on long-term memory
differentiation. Long-term memory populations of CD8+ T cells exhibit higher mitochondrial
biomass and higher oxidative phosphorylation298,299 and blocking oxidative phosphorylation with
with high dose etomoxir reduces function. CD8+ T cells that are forced to use glycolysis rather
than oxidative phosphorylation preferentially create effector memory populations, rather than
central memory300, and blocking glucose metabolism increases central memory T cells 301.
Blocking polyamine metabolism results in phenotypic similarities to central memory T cells,
suggesting that polyamine production drives effector memory differentiation. The function of any
memory cells with lower polyamine pools has yet to be determined.
Further supporting the hypothesis that blocking polyamine metabolism increases CD8+
T cell long-term memory function is the skewing of normal asymmetric cell division. There are
several theories explaining T cell differentiation into effector and memory T cell function.
Asymmetric cell division is one such theory in which activated naive T cells asymmetrically
distribute protein, organelles and RNA resulting in daughter cells with different fates 14,234,302.
These first generation daughter cells exhibit differing phenotypes. For example, T cells with
lower levels of Myc, CD8 and mTOR have memory function characterized by elevated oxidative
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phosphorylation, mitochondrial content, CD62L expression, and recall response. Following this
theory, it is evident that blocking polyamines causes the accumulation of cells containing lower
amounts of CD8 and Myc protein. Thus, limiting polyamine metabolism could increase long-term
memory T cell function.
The hypothesis that polyamines increase effector function is especially interesting in light
of the effects of Cereblon (CRBN), a regulator of the polyamine pathway in activated CD8 + T
cells. It is evident that CD8+ T cells lacking CRBN increase short-term effector function in vivo
and in vitro, as demonstrated by increased glucose metabolism, cytokine production and
expression of effect function genes. Given the increase in polyamines, inhibiting CRBN could
have negative consequences on long-term CD8+ T cell memory responses. Some of the data
presented here is in conflict with this hypothesis. For instance, homeostatic-driven memory
development during the aging process in mice lacking CRBN enriches long-term CD8+ T cell
memory. CRBN-deficient CD8+ T cells also have increased glutamine and arginine uptake,
which could drive a positive anti-tumor response or general immune response, overcoming any
negative consequences of increased polyamine production. High levels of arginine are
beneficial to long-term T cell immunity and survival, possibly through alterations in pathways
outside of polyamine production44. Several studies also indicate that Myc protein expression is
essential to both viral long-term memory development30 3 and homeostatic proliferation induced
memory304. Other pathways outside of glutamine and arginine metabolism could aid in Mycdriven long-term immunity. Further, cellular machinery that turns off Myc mRNA and protein
expression appears to be in tact in CRBN-deficient CD8+ T cells. Therefore, detrimental effects
of overexpressed Myc in CD8+ T cells could also be dampened in the absence of CRBN.
Given the role of polyamine production on asymmetric division and the distribution of
Myc to daughter cells, it is essential to observe any effect CRBN has on asymmetric division.
Outside of the work presented here, previous studies have also demonstrated that inhibiting
amino acid uptake and glutaminase disrupts T cell asymmetric cell division processes 14,234. The
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increased Myc expression and polyamines observed in the absence of CRBN could accumulate
the inheritance of Myc protein to all daughter cells, ultimately skewing the first generation
population toward Myc hi effector cells. However, adding exogenous arginine or a mix of amino
acids does not have an effect on asymmetric division14. It is therefore possible that normal
asymmetric division occurs in the first generation of CD8 + T cells in the absence of CRBN, but
more Myc hi effector cells accumulate in undivided cells and subsequent generations.
Future work on polyamine biosynthesis, CRBN and long-term memory CD8+ T cells will
increase the translatability of these findings. Both polyamine biosynthesis and CRBN are easily
targetable through small molecules described in this work. Immunotherapy to treat cancer is
rapidly expanding to different types of cancer and will require more modifications to increase the
durability of responses. For example, tumor-infiltrating lymphocytes (TILs) exhibit dysfunctional
mitochondrial activity305, resulting in low anti-tumor immunity. Expanding TIL ex vivo in the clinic
for re-infusion to the patient is a popular immunotherapeutic technique in cancers like
melanoma306. During this process, a patient’s TIL are removed from tumor fragments and
rapidly expanded in the effector molecule, IL-2. Different T cell memory populations can
increase the response to TIL therapy307,30 8, and it has been proposed that increasing memory T
cells during the TIL rapid expansion process by adding cytokines other than IL-2 or genetic
modification can enhance patient response306. Adding DFMO or immunomodulatory drugs
during the expansion process to increase the function, metabolism and memory of TIL would be
a safe and easy way to increase patient responses.
Another immunotherapeutic strategy to treat hematological malignancies is the addition
of chimeric antigen receptor (CAR) to a patients T cells. Similar to tumor-infiltrating lymphocytes
in solid tumors, T cells from patients with hematological malignancies have impaired
metabolism, including decreased glucose metabolism 33. Increasing metabolic potential of CAR
T has been shown to be more successful for patients receiving CAR T cells 309 and using CAR
constructs with higher metabolic potential is desirable239. Production of CAR T cells is similar to
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the process of TIL therapy in that there is an activation of patients’ T cells ex vivo to introduce
the CAR construct. There is therefore a window to target pathways that regulate metabolism,
such as polyamine production or CRBN.
The Treg population enriched with recent UV exposure warrants more investigation.
Several studies have demonstrated that overall numbers of Tregs are expanded with chronic
long-term UV exposure15 3,281, but more investigation into why acute UV has such an effect on
Tregs could be interesting in the future. These could aid in understanding the role of the
immune system during UV-induced or UV-related carcinogenesis. Further, following this same
cohort of patients could aid in understanding changes in Treg populations and skin cancer
development.
Ultimately, these studies serve as the basis for work that will be directly translatable to
the clinic, from immunotherapy, cancer prevention, and basic immunology.
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